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ABSTRACT 
Vitamin D metabolites are important in the regulation of bone and calcium 
homeostasis, but also have a more ubiquitous role in the regulation of cell differentiation 
and immune function. Severely low circulating 25-dihydroxyvitamin D [25(OH)D] 
concentrations have been associated with the onset of active tuberculosis (TB) in 
immigrant populations, although the association with latent TB infection (LTBI) has not 
received much attention. A previous study identified the prevalence of LTBI among a 
sample of Mexican migrant workers enrolled in Canada's Seasonal Agricultural Workers 
Program (SA WP) in the Niagara Region of Ontario. The aim of the present study was to 
determine the vitamin D status of the same sample, and identify if a relationship existed 
with LTBI. 
Studies of vitamin D deficiency and active TB are most commonly carried out 
among immigrant populations to non-endemic regions, in which reactivation of LTBI has 
occurred. Currently, there is limited knowledge of the association between vitamin D 
deficiency and LTBI. Entry into Canada ensured that these individuals did not have active 
TB, and L TBI status was established previously by an interferon-gamma release assay 
(IGRA) (QuantiFERON-TB Gold In-Tube®, Cellestis Ltd., Australia). Awareness of 
vitamin D status may enable individuals at risk of deficiency to improve their nutritional 
health, and those with LTBI to be aware of this risk factor for disease. 
Prevalence of vitamin D insufficiency among the Mexican migrant workers was 
determined from serum samples collected in the summer of 2007 as part of the cross 
IV 
sectional LTBI study. Samples were measured for concentrations of the main circulating 
vitamin D metabolite, 25(OH)D, with a widely used 1251 250HD RIA (DiaSorin Inc.®, 
Stillwater, MN), and were categorized as deficient «37.5 nmoI/L), insufficient (>37.5 
nmollL, < 80 nmol/L) or sufficient (2::80 nmoI/L). Fisher's exact tests and t tests were used 
to determine if vitamin D status (sufficiency or insufficiency) or 25(OH)D concentrations 
significantly differed by sex or age categories. Predictors of vitamin D insufficiency and 
25(OH)D concentrations were taken from questionnaires carried out during the previous 
study, and analyzed in the present study using multiple regression prediction models. 
Fisher's exact test and t test was used to determine if vitamin D status or 25(OH)D 
concentration differed by LTBI status. Strength of the relationship between interferon-
gamma (IFN-y) concentration (released by peripheral T cells in response to TB antigens) 
and 25(OH)D concentration was analyzed using a Spearman correlation. 
Out of 87 participants included in the study (78% male; mean age 38 years), 14 
were identified as LTBI positive but none had any signs or symptoms of TB reactivation. 
Only 30% of the participants were vitamin D sufficient, whereas 68% were insufficient 
and 2% were deficient. Significant independent predictors of lower 25(OH)D 
concentrations were sex, number of years enrolled in the SA WP and length of stay in 
Canada. No significant differences were found between 25(OH)D concentrations and 
LTBI status. There was a significant moderate correlation between IFN-y and 25(OH)D 
concentrations ofLTBI-positive individuals. 
The majority of participants presented with Vitamin D insufficiency but none were 
severely deficient, indicating that 25(OH)D concentrations do not decrease dramatically 
v 
in populations who temporarily reside in Canada but go back to their countries of origin 
during the Canadian winter. This study did not find a statistical relationship between low 
levels of vitamin D and LTBI which suggests that in the presence of overall good health, 
lower than ideal levels of 2S(OH)D, may still be exerting a protective immunological 
effect against LTBI reactivation. The challenge remains to determine a critical 2S(OH)D 
concentration at which reactivation is more likely to occur. 
VI 
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CHAPTER ONE: INTRODUCTION 
Vitamin D is primarily recognized for its effects on bone health. Although it is 
referred to as a vitamin by name, its ability to be produced endogenously and the function 
of its metabolites as intercellular messengers denotes that vitamin D, in fact, acts as a 
hormone [1]. Recently, the regulatory properties of the hormone have been described for 
multiple biological processes and its deficiency has been established as a risk factor for 
several chronic and infectious diseases, particularly tuberculosis (TB) [2]. 
The role of vitamin Din combating Mycobacterium tuberculosis, the causal agent of 
TB, has been observed and applied since the 1800s. During this time, exposure to sunlight 
and the administration of cod liver oil (both sources of vitamin D) were observed as 
having beneficial effects for TB patients in sanatoria, who were said to have regained 
their strength within days [3, 4]. The biological mechanisms leading to the health 
improvement of TB patients undergoing these treatments were unknown at the time, but 
became evident when vitamin D was isolated from cod liver oil in 1922 by Elmer V. 
McCollum [5]. Oral doses of vitamin D were administered routinely to TB patients until 
the discovery of TB antibiotics in the 1940s, from which time its use to treat TB began to 
lessen within the mainstream medical community [2]. 
After many decades of seemingly ignoring the potential role of vitamin D as 
supplementary aid in the treatment of TB, increasing evidence now confirms that there is 
a significant association between decreased vitamin D levels and active TB disease [6]. 
This is especially true in patients belonging to certain ethnic groups [7, 8], immigrants to 
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non-endemic countries [9], and others in whom insufficient cutaneous synthesis or dietary 
intake may lead to hypovitaminosis D [6, 10, 11]. 
Supporting evidence for the contribution of vitamin D to improved host resistance 
to TB is derived from the recent elucidation of the mechanism by which the biologically 
active fonn of vitamin D, la,25-dihydroxyvitamin D (l,25(OH)2D), enhances the 
antituberculous response of macrophages, cells of the innate immune system which are 
the main targets for M tuberculosis infection. 
This newly established link between the honnonally active metabolite and the innate 
immune system has greatly contributed to the increasing interest in investigating the 
beneficial role of vitamin D not only in active TB, but in latent infection as well [12]. In 
latent TB infection (LTBI), mycobacteria evade intracellular killing by inhibiting the 
fusion of the phagosome and lysosome within the macrophage. It has been shown that 
vitamin D metabolites can reverse this inhibition by promoting phagolysosomal fusion 
[13]. Thus, the role of vitamin D in the prevention of LTBI reactivation is worth 
exploring. If proven beneficial, vitamin D supplementation in individuals with 
demonstrated LTBI could potentially reduce the global burden of one of the world's most 
widespread diseases [14]. The present study will investigate vitamin D deficiency as a risk 
factor for TB reactivation in an otherwise healthy population from a TB-endemic country. 
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CHAPTER TWO: LITERATURE REVIEW 
Though commonly referred to as the "sunshine vitamin", vitamin D metabolites act 
as hormones and have long been acknowledged to be essential for the proper development 
of bones, especially in the prevention of rickets among children. During 18th and 19th 
centuries, the Industrial Revolution [15] led a large number of people to relocate from 
rural to urban homes and jobs. Urban habitation often resulted in increased malnutrition, 
indoor employment and increased smog exposure that reduced exposure to sunlight. 
During this time, there was an increase in the incidence of rickets, a softening of the bones 
due to vitamin D deficiency [16, 17]. From 1918 to 1922, the ability of cod liver oil to 
reverse the symptoms of rickets was recognized and described by Edward Mellanby and 
Elmer V. McCollum [18, 19). The substance providing these protective properties was 
subsequently isolated and named vitamin D in 1922, by McCollum [5]. Recently, vitamin 
D has been receiving increased attention for its role in maintaining health and homeostasis 
in a variety of essential body processes, and in the prevention of numerous chronic and 
infectious diseases [20, 21). The protective role of vitamin D against active TB disease 
extends back to the 1800s, when the benefits of cod liver oil and sunlight were applied as 
TB therapies [2]. 
2.1 The Vitamin D Molecule 
There are two forms of vitamin D, vitamins D2 and D3, which can be utilized by 
humans. Both can be intestinally absorbed, vitamin D2 by the consumption of some plants 
and mushrooms and vitamin D3 by the consumption of fatty fish and fortified foods [22]. 
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Generally, vitamin D3 is endogenously produced in the skin in response to ultraviolet B 
(UVB) radiation. Vitamins D2 and D3 are biologically inert molecules, and must go 
through a series of enzymatically induced alterations, producing multiple metabolites, 
before biologically active forms are produced [23]. 1,25(OHhD is the biologically active 
metabolite, although 25(OH)D is most frequently measured. Table 1 summarizes the main 
functions of these metabolites. The critical molecular difference from the D2 forms is in 
the ring B structure. The remainder of the document will use vitamin D to refer to either 
D2 or D3, unless otherwise specified. 
Table 1: The structures and functions of selected vitamin D metabolites and other 
associated molecules*. 
7 -dehydrocholesterol 
(or 5,7-cholestradienol) 
Pre-vitamin D3 
(or precalciferol) 
Vitamin D3 
(or cholecalciferol, 
calciol) 
Pre-vitamin D2 
(or ergosterol) 
25 
25 
An inert molecule in the skin 
that absorbs UVB radiation of 
290-315 nm at the two double 
bonds of ring B. 
Thermodynamically unstable 
molecule that isomerizes 
within 2-3 days, acting as the 
mediator between 7-DHC and 
vitamin D3. 
Produced in the skin by the 
UVB irradiation of pre-
vitamin D3, and diffuses into 
the blood, through which it is 
carried by DBP. 
A common steroid produced 
by plants which is converted 
to vitamin D2 following UVB 
irradiation. 
Vitamin D2 
(or ergocalciferol) 
25-hydroxyvitamin D3 
(or calcidiol) 
1,25-dihydroxyvitamin 
D3 (or calcitriol) 
Lumisterol 
Tachysterol 
25 
OH 
OH 
OH 
5 
Analogue of vitamin D in 
plants which is derived from 
the UVB irradiation of pre-
vitamin D2. This is a dietary 
source of vitamin D. 
Produced in the liver by the 
hydroxylation of vitamin D3 
(pictured) or D2. It is the most 
commonly circulating form of 
vitamin D, making it a good 
biomarker for vitamin D 
status, although it is 
biologically inert. 
Produced primarily III the 
kidneys by the hydroxylation 
of 25(OH)D3, it IS the 
hormonally active form of 
vitamin D. 
Produced by the irradiation of 
7-DHC. This molecule is 
biologically inert and IS 
naturally sloughed off with the 
skin. 
Synthesized by the further 
irradiation of pre-vitamin D3. 
This molecule is biologically 
inert and is naturally sloughed 
off with the skin. 
* Adapted from Holick [24JJohnson et al [23J ,Peleg et al [25J, Fraser et al [26J, Kobori et al [27J, 
Orlova et al [28J, Caballero et al [29J, Gropper et al [30). 
DBP, Vitamin D binding protein; UVB, ultra violet blue; 7-DHC, 7-dehydrocholesterol 
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2.2 Sources of Vitamin D 
2.2.1 Dietary Sources 
Vitamin D is a unique molecule, as it can be both endogenously synthesized and 
obtained through diet or supplements. Animals are only able to synthesize vitamin D3, 
while plants and mushrooms produce only vitamin D2. The primary dietary source of 
vitamin D3 is the flesh of oily fish. A common steroid produced by plants is ergosterol (or 
pre-vitamin D2), which is converted to vitamin D2 following UVB irradiation [22]. 
In 1997, the Dietary Reference Intakes for the Institute of Medicine [31] in the 
United States established the adequate intake (AI) of vitamin D for males and females at 
different ages, as depicted below in Table 2. The AI values were determined by the levels 
of dietary vitamin D required to prevent a wintertime decrease in serum 25(OH)D 
concentrations among adults 19-50 years of age [32]. 
Table 2: The recommended adequate intake of vitamin D (ill/day) 
for males and females of various * 
:::;50 years 
(and all pregnant and 
lactating women) 
51-70 years 
>70 years 
200 
400 
600 
5 
10 
15 
* Adequate intake is converted from IU/day to Ilg/day by multiplying by 40 
The established consensus on the adequate intake (AI) of vitamin D has met with 
inconsistencies. Despite the above recommendations, the Canadian Paediatric Society 
recommends an AI of 400 ill/day for infants and the Canadian Osteoporosis Society 
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recommends an AI of 800 IV/day for adults 2':51 years at risk of osteoporosis [33]. As 
well, multiple studies have shown that these AI values may not be adequate enough to 
meet daily vitamin D requirements. For example, a Canadian study [34] of adults (ages 
ranging 27-89 years) showed that almost everyone taking the recommended 200 IU/day 
vitamin D supplementation still had insufficient 25(OH)D concentrations «80 nmol/L) at 
least one time during the year, indicating that the recommended daily intake levels may 
not be adequate. Bischoff-Ferrari and colleagues [21] carried out a review of serum 
25(OH)D concentration thresholds, concluding that optimal 25(OH)D concentrations 
begin at 75 nmollL. This conclusion was based on findings that bone mineral density 
(BMD) and dental health were improved, while fractures and colorectal cancer were 
prevented. Further, 25(OH)D concentrations 2':75 nmollL could not be reached with the 
current recommended daily intakes of 200-600 IV vitamin D. In another review, Vieth 
[35] reasoned that at least 800 IV/day are required to promote overall good health. In fact, 
Lu and colleagues [36] stated that without adequate sun exposure, dietary vitamin D 
should be at least 1000 IV/day. Since one full body VVB exposure has been shown to 
yield serum 25(OH)D concentrations equivalent to one vitamin D supplementation dose 
of 10,000 IV, and current AI recommendations may need reassessment [35]. As well, the 
absence of toxicity in clinical trials using this vitamin D supplement dose indicates that 
this may be an appropriate upper intake level of vitamin D [37]. 
As depicted above in Table 2, AI values differ with respect to age. Studies of the 
25(OH)D concentrations of older age groups have shown that recommended levels may 
be inadequate to maintain vitamin D sufficiency, as indicated in the following two studies 
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of women in the United States. Firstly, Lappe and colleagues [38] found that women aged 
55 years and over taking vitamin D supplementation of 1100 IU/day for four years, were 
found to have an average increase in serum 25(OH)D concentration of approximately 23.9 
nmol/L, raising the serum concentration to greater than 80 nmol/L, considered the level of 
sufficiency. Secondly, Aloia and colleagues [39] found that serum 25(OH)D 
concentrations were only increased above 80 nmol/L after supplementation of 2000 
IU/day. 
Monitoring vitamin D intake through dietary consumption may be problematic at 
times. As previously stated, vitamin D is absorbed from some naturally occurring foods, 
such as fatty fish, but some foods, such as milk and margarine, are vitamin D-fortified. 
Fortification systems may have inconsistencies, resulting in inaccurate estimations of 
dietary vitamin D intake. For example, a study of Aboriginal and non-Aboriginal 
Canadian women reported that although each participant was meeting the AI of dietary 
vitamin D, primarily through the consumption of fortified milk and margarine, vitamin D 
deficiency (in this study defined as serum 25(OH)D concentration <37.5 nmollL) was 
found in all participants [40]. This may have been due, in part, to discrepancies in the 
fortification system of foods in North America. Despite the fact that Canada and the US 
fortify milk with approximately 385-425 IU vitamin D per litre of milk [41, 42], 49% of 
milk samples tested in the US and British Columbia contained less than 80% of the 
vitamin D content on the label and 14% did not have any detectable levels of vitamin D 
[43]. This may lead to deficiencies in individuals living at high latitudes, who rely on 
dietary vitamin D during a portion of the year. 
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Similarly, the vitamin D3 content of fish has shown variation. For example, Lu and 
colleagues [36] have demonstrated that wild-caught salmon contained approximately 988 
IU vitamin D311 00 g serving, while the vitamin D3 content of farmed salmon was 
approximately 25% that of wild salmon. As well, it should be noted that while cooking 
salmon had a negligible effect in this study, frying in vegetable oil reduced vitamin D3 
content by about 50%. 
2.2.2 Sun Exposure 
Humans are capable of cutaneously producing vitamin D3 in response to UVB 
exposure, and this is the most abundant source of vitamin D for most humans [44]. The 
human sebaceous glands produce 7-dehydrocholesterol (7-DHC), an inert molecule that is 
secreted and evenly distributed throughout the epidermal and dermal layers of the skin 
[30]. The two double bonds of ring B of7-DHC (Table 1) absorb UVB radiation (290-315 
nm wavelength) that converts the molecule to pre-vitamin D3. Within 2-3 days, pre-
vitamin D3 is thermally isomerized into vitamin D3 and diffuses from the skin into the 
blood, through which it is transported by the transport a-2 globulin vitamin D-binding 
protein (DBP) (Figure 1) [24,45]. 
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SKIN 
Figure 1: Cutaneous production of pre-vitamin D3 following UVB exposure [24] 
In order to prevent vitamin D toxicity, there are control mechanisms in place. Other 
molecules produced during UVB irradiation are lumisterol and tachysterol, synthesized by 
the further irradiation of pre-vitamin D3 (Figure 1 and Table 1). These compounds are 
biologically inert and are naturally sloughed off with dead skin cells, thereby preventing 
the overproduction of vitamin D3 in the skin resulting from sunlight over-exposure [46]. 
Also contributing to the prevention of endogenous overproduction, is the degradation of 
vitamin D3 in response to excess sunlight exposure [47]. 
Regardless of diet, the greatest source of vitamin D is through cutaneous production 
by way of UVB radiation. As previously stated, the wavelength of UVB ranges between 
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290-315 run, and its absorption by the skin is dependent on various factors, stemming 
from the sun's position during different times of the year [24]. The amount of UVB that 
reaches the biosphere is affected by the zenith angle of solar radiation and the amount of 
ozone in the atmosphere, which absorbs UVB very efficiently. These factors are 
dependent on latitude, season, and time of day. The zenith angle changes with the daily 
rotation of the Earth, and is a measure of the angle at which the sun's rays reach the earth. 
As the zenith angle reaches 90°, a greater amount of UVB is available for absorption. At 
higher latitudes, especially during the winter months, the shorter wavelengths of UVB are 
absorbed and scattered by the atmosphere. This leaves the inhabitants of higher latitudes 
with reduced exposure, which will in turn result in less synthesis and subsequent 
absorption of vitamin D in the skin [43, 48]. As well, between October and March, 
individuals living at latitudes greater than 42° north or south are not exposed to sufficient 
UVB photons for cutaneous vitamin D3 production (Figure 2) [49]. This includes the 
Niagara Region of Ontario, where the present study was carried out. Figure 3 shows the 
impact of latitude on the level of UVB radiation available for cutaneous production of 
vitamin D, with equatorial regions experiencing year-round vitamin D production, and 
regions at approximately 400N latitude and above experiencing some months with no 
UVB exposure and therefore no vitamin D production [48]. 
Figure 2: Map of latitude lines and major cities around the world 
(Taken from: Sky and Telescope, 2008 [50]) 
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Figure 3: Impact of latitude on the level of UVB radiation available for cutaneous 
production of vitamin D by month (Adapted from: Kimlin, 2008 [48]) 
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Because UVB radiation is a known human carcinogen, public health agencIes 
recommend wearing sunscreen protection. However, the application of sunscreen has 
been shown to reduce synthesis of vitamin D3 in the skin by blocking UVB radiation [51, 
52]. Therefore, the practices of Western culture playa role in reducing cutaneous 
production of vitamin D3 and contribute to the prevalent vitamin D insufficiency in this 
population. 
Melanin acts as a natural sunscreen by absorbing UVB photons, thereby competing 
with 7-DHC in the skin. At a latitude of 42°, race was found to influence the conversion 
of 7-DHC to pre-vitamin D3, as Whites experienced 5-10 fold greater conversion than 
Blacks [43]. As well, an in vitro study by Liu and colleagues [l4J showed that the serum 
25(OH)D concentration of Blacks (approximately 23 nmollL) was much lower than that 
of Whites (approximately 78 nmoI/L). Therefore, individuals with darker skin must spend 
longer periods of time in the sun in order to endogenously produce the same amount of 
vitamin D3 as lighter skinned individuals [49]. Migration of dark-skinned individuals to 
countries at higher latitudes leads to a reduced cutaneous production of vitamin D3, an 
effect that is exacerbated during the winter months [29]. In order to produce sufficient 
vitamin D3, Blacks may require 5-50 fold more time exposed to DVB radiation than 
Whites [23]. 
In addition to sun exposure, endogenous vitamin D3 production also depends on the 
concentration of 7-DHC in the skin. The concentration of 7-DHC has an inverse 
relationship with age [23, 49J, which account for the finding that the continuous vitamin 
D production of a 70 years old is approximately four fold less than that of a 20 year old 
14 
[44]. Similarly, MacLaughlin and Holick [53] found a 50% reduction in 7-DHC in 
individuals 80 years of age when compared to 20 year olds. This results in circulating 
concentrations of 25(OH)D among elderly individuals that are 30% of those of young 
adults [49]. This is the reason Health Canada has recommended that the daily vitamin D 
intake of adults older than 50 years be twice that of younger adults, although this may not 
be adequate [54]. A recent report released by the Public Health Agency of Canada 
(PHAC) [55] on the impacts of falls among the elderly has stated that adults 65 years and 
up should actually be consuming at least 800 IU vitamin D per day. 
2.3 Normal Levels of Circulating Vitamin D 
Measures of serum 25(OH)D concentrations are used most often to determine the 
vitamin D status of individuals. It is very difficult to determine the circulating 25(OH)D 
concentration cut-points that classify "normal" or "sufficient" vitamin D status, and 
therefore those concentrations that would indicate a deficient or insufficient status. 
Researchers have asserted that determining sufficient circulating concentrations of 
25(OH)D should acknowledge that humans have not evolved in an environment of sun 
avoidance [56]. An optimal range should therefore be based on the concentration of 
individuals who are continuously exposed to high UVB or living close to the equator, 
without being overly clothed and without sunblock protection. For that reason, the 
25(OH)D concentrations of fieldworkers, construction workers and sunbathers have been 
recommended for establishing an optimal circulating 25(OH)D range for humans [47, 57]. 
Individuals who spend their days unprotected from UVB radiation have been reported as 
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having circulating 25(OH)D concentrations ranging from approximately 100-200 nmol/L 
[56]. 
A consensus as to what the maximum serum concentration of 25(OH)D should be 
has not been reached. At a recent round table discussion in 2005 [58], leading experts 
recommended that optimal concentrations of circulating 25(OH)D should be maintained 
at a minimum of approximately 75-80 nmollL. Cut-points for establishing deficient, 
insufficient and sufficient concentrations of serum 25(OH)D have been determined by 
evaluating biomarkers of the biological function of vitamin D and its homeostasis with 
calcium, such as calcium absorption, parathyroid hormone (PTH) production, BMD and 
bone fractures. Table 3 provides an outline of how these factors have been used to 
establish "sufficient" and "deficient" cut-points for vitamin D status. 
2.3.1 The Role of Parathyroid Hormone in Establishing Cut-Points 
When evaluating 25(OH)D cut points, an important factor to take into consideration 
IS that increasing age has a significant effect on the body's vitamin D requirement. 
Among the elderly, secondary hyperparathyroidism is an indicator of poor vitamin D 
nutritional status, as the inverse relationship between PTH and serum 25(OH)D 
concentrations becomes more pronounced with age [47]. This inverse relationship ensures 
that as serum 25(OH)D concentrations begin to fall, PTH begins to be synthesized and 
secreted. Interestingly, this effect begins to subside as serum 25(OH)D concentrations 
approach 75-80 nmollL, and PTH levels reach their optimal physiological concentrations 
and plateau [47, 56, 59, 60]. 
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2.3.2 The Role of Calcium Absorption and BMD in Establishing Cut-Points 
Calcium absorption may also act as a functional end point when determining 
optimal concentrations of circulating 25(OH)D. At a 25(OH)D concentration of 80 
nmollL, calcium absorption reaches a threshold, but begins to decrease as 25(OH)D 
concentrations drop below 80 nmol/L [47, 56]. Calcium absorption may be an important 
factor in determining vitamin D deficiency cut points. The presence of bone diseases, 
such as rickets among the young and osteomalacia among adults, are significantly 
increased when 25(OH)D concentrations are below 12.5 nmol/L, although levels 
maintained at less than 25 nmol/L over long time periods may also increase disease 
development [23, 57]. Many clinicians, assay manufacturers and clinical chemical 
laboratories, recognize the cut-point of 25(OH)D deficiency as being approximately 25 
nmol/L [47]. Table 3 provides a summary of cut-points, as determined by the analysis of 
PTH concentrations, calcium absorption and bone fractures. 
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Table 3: Cut-points of circulating 2S(OH)D concentrations established by various 
researchers, and the cut point justifications * 
2:80 nmol/L (sufficient) 
<22.S nmollL (deficient) 
• 96% of women with hip fractures 
have circulating 2S(OH)D <80 
nmol/L 
• One year after fracture event, those 
with levels <22.S nmol/L have 
higher fall rates and poorer tests for 
the performance level of lower 
extremities 
~ 100 nmol/L (sufficient) • Prevention of hip and all non-
vertebral fractures with 2S(OH)D 
levels of 100 nmol/L 
90-100 nmol/L (sufficient) • BMD continued to increase among 
young White and Mexican 
American individuals with 
circulating 2S(OH)D levels> 1 00 
nmol/L 
LeBoff et aI, 2008 
[61] 
Bischoff-Ferrari et ai, 
200S [62] 
Bischoff-Ferrari et aI, 
2004 [63] 
37.S nmol/L (deficient) • Serum PTH levels start increasing if Arya et aI, 2004 [64] 
circulating 2S(OH)D levels decrease 
<12.S nmol/L (severely 
deficient) 
~80 nmol/L (sufficient) 
~SO nmol/L (deficient) 
below 37. S nmollL 
• Intestinal calcium absorption 
significantly increased by ~6S% 
with an increase of2S(OH)D levels 
from SO nmol/L to 80 nmol/L 
Heaney et aI, 2003 
[6S] 
7S-80 nmol/L (sufficient) • Optimal calcium absorption Holick et aI, 200S [66] 
• PTH levels elevated in only 10% of 
the participants 
<20 nmol/L (deficient) • Obvious signs of deficiency occur, Moore et aI, 2005 [67] 
such as bone pain and reduced BMD 
~80 nmol/L (sufficient) • Risk of all cancers was reduced 3S% Lappe et aI, 2007 [38] 
80-90 nmol/L (sufficient) 
37.S nmol/L (deficient) 
100 nmol/L 
among healthy, postmenopausal 
women 
• Risk of colorectal cancer was 46% 
lower among women with 88 
nmol/L versus 37.S nmol/L 
[2S(OH)D] 
Feskanich et aI, 2004 
[68] 
• Risk of multiple sclerosis was 62% Munger et aI, 2006 
lower, particularly when measured [69] 
in young women <20 years 
* Serum 25(OH)D concentration cut points classify vitamin D status as sufficient, insufficient or deficient 
** Serum 25(OH)D concentration is converted from nmoVL to ng/mL by dividing by 2.496 
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2.4 Detection of Vitamin D Metabolite Concentrations 
Assuring adequate levels of vitamin D is essential for overall health. This requires 
the accurate measurement of vitamin D metabolite concentrations. However, vitamin D 
determination is hindered by various challenges. As previously stated, vitamin D status is 
most often established by measuring circulating 25(OH)D concentrations. Although 
1,25(OHhD concentrations may also be measured to analyze vitamin D status, assays 
quantifying the hormonally active metabolite have not been as widely evaluated [70] and 
serum concentrations of 1,25(OHhD may not be a reliable measure of vitamin D status. 
This is because it is less abundant in circulation and has a shorter half-life than its 
precursor 25(OH)D, which makes up approximately 94% of circulating vitamin D 
metabolites and has a half-life of about three weeks [49, 71]. Conversely, the half-life of 
1,25(OH)2D is about 4-6 hours [71], and it circulates at concentrations about 1000 times 
lower than 25(OH)D [59]. 
Hepatic production of 25(OH)D is primarily dependent on the availability of 
, 
vitamin D, and is not strongly regulated by other factors [72J. In contrast, 1,25(OHhD 
concentrations may fluctuate according to parathyroid hormone (PTH) concentrations. 
During vitamin D deficiency, intestinal calcium absorption is reduced, which triggers the 
production and secretion of PTH from the parathyroid glands. In turn, PTH increases 
calcium resorption and renal 1,25(OH)2D production, Therefore, vitamin D deficient 
individuals with normal renal function may show either normal or elevated levels of 
1,25(OHhD [45J. 25(OH)D is the vitamin D metabolite that was measured and analyzed 
in the present study, and is a measure of the exposure and supply of the nutrient to target 
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tissues. The following describes the gold standard test for measuring circulating 25(OH)D 
concentrations, as well as the assay utilized in the present study and the rationale for its 
use. 
2.4.1 The Gold Standard Test 
In 1977, the high performance liquid chromatography (HPLC) method of directly 
detecting circulating 25(OH)D was introduced. HPLC allows for large amounts of crude 
serum to be analyzed in a short amount of time with high specificity and sensitivity, and is 
considered to be the gold standard test [73 J. HPLC is used to separate the components of a 
mixture, in this case 25(OH)D2 and 25(OH)D3, for identification and quantification by 
UV detection methods. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
is employed as well, which utilizes mass spectrometry to quantify vitamin D levels [74J. It 
is also able to separate and accurately quantify 25(OH)D2 and 25(OH)D3 [75J. These 
methods are not always available to clinical laboratories, due to the high financial costs 
involved, and need for highly trained and experienced personnel to operate the 
instruments [76]. This is why simpler, more cost-effective methods are required. 
2.4.2 Radioimmunoassay 
The principle behind radioimmunoassays (RIA) involves the ability of high-affinity 
anti-antigen antibodies to competitively bind with a known amount of radioactively-
labelled antigen and unlabelled antigen [77J. The radioisotope 1251 is the most commonly 
used when performing a RIA, because iodination of proteins occurs without the disruption 
of their immune specificity [74]. Separation of the 25(OH)D-antibody complex allows for 
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the amount of labelled 25(OH)D-antibody to be measured. A large amount of labelled 
25(OH)D-antibody indicates that only a small amount of 25(OH)D is available in the 
serum sample to compete, and therefore the serum 25(OH)D concentration in the sample 
is small. Conversely, a small amount indicates that a large concentration of 25(OH)D is 
present in the serum sample. Gamma radiation of 125I-Iabelled 25(OH)D-antibody is 
measured and quantification of the 25(OH)D concentration is determined by a standard 
curve [77]. 
2.4.3 Choosing a Method to Measure Serum 25(OH)D Concentration 
Since 1989, all methods of determining vitamin D status have been regularly 
analyzed by the Vitamin D External Quality Assessment Scheme (DEQAS), in order to 
improve the precision and accuracy of available assays [78]. Two of the main 25(OH)D 
assays being tested and utilized within the research community are the chemiluminescent 
competitive protein-binding Nichols Advantage® 25-0H Vitamin D (developed by 
Nichols Institute Diagnostics) and the DiaSorin 25-0H Vitamin D Radioimmunoassay® 
(developed by DiaSorin). The main difference between the two assays is that DiaSorin 
RIA® uses an antibody to 25(OH)D, whereas Nichols Advantage® uses a DBP [79]. 
A study by Binkley and colleagues [80] looked at the variation between assays and 
the potential to confound diagnosis in a clinical setting. The study assigned serum samples 
to eight different labs, each having to establish 25(OH)D concentrations by a specific 
method. Three labs used the Nichols Advantage® assay, two implemented the DiaSorin 
RIA®, and one used the gold standard HPLC (two labs used other methods). The study 
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showed substantial variation in the serum 25(OH)D concentrations detennined by 
different labs using the same and different methods. The proportion of individuals falling 
below the pre-detennined sufficiency cut-point of 80 nmollL varied by 17-90%. The 
Nichols Advantage® assays all produced overestimated values of the basal 25(OH)D 
concentrations and underestimations of exogenously added 25(OH)D2. The Nichols 
Advantage® assay yielded a poor comparison to the HPLC method, while DiaSorin 
RIA® showed a good comparison with the gold standard HPLC in the study. Similar 
results were obtained by Terry and colleagues [79], who found that the Nichols 
Advantage® yielded values less than 40% the values of the gold standard. 
DEQAS has repeatedly reported that 25(OH)D2 and 25(OH)D3 are detected 
accurately with the DiaSorin RIA® assay. Conversely, DEQAS suggests that Nichols 
Advantage® competitive protein-binding assay is not capable of properly detecting 
25(OH)D2, and frequently leads to underestimations of total 25(OH)D concentrations, as 
both metabolites are found in serum [70, 73, 81]. This is in contrast to the manufacturer's 
labelling, which claims that Nichols Advantage® will have 100% cross-reactivity 
between 25(OH)D2 and 25(OH)D3. As a result, many studies report that the Nichols 
Advantage® assay shows a significant discrepancy with the gold standard HPLC [70, 73, 
76], and is the reason it has not been implemented in the present study. 
Discrepancies between DiaSorin RIA® testing laboratories have highlighted the fact 
that a lack of experience with the assay, and a lack of validation within the lab can likely 
lead to variable and unreliable results [73]. In the present study, maintaining reliable 
results with the DiaSorin RIA® was ensured by the use of quality control measures. For 
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example, assay perfonnance was monitored usmg two controls, at a low-nonnal 
concentration and at a high-nonnal concentration, which were provided by the assay kit 
manufacturers. As well, the controls, along with the unknown samples and standards were 
assayed in duplicate. Intra-assay coefficient of variation (CV) (calculated by dividing the 
mean 25(OH)D concentration by the standard deviation) greater than 10% required re-
assaying. Similarly, sample 25(OH)D concentrations above 70 ng/mL (175 nmol/L) or 
the lowest standard 5.0 ng/mL (12.5 nmollL) were verified by re-extraction and re-assay 
(samples with concentrations above 100 ng/mL (250 nmollL) were diluted before re-
extraction). 
2.5 Vitamin D Metabolism 
As previously discussed, vitamin D can be taken in by diet or exposure to UVB 
radiation. Once it is ingested, dietary vitamin D is ahsorbed in the intestines. Since 
vitamin D is a fat-soluble molecule, it must be consumed with lipids for proper 
absorption. Dietary vitamin D is absorbed from a micelle with fat, and broken down with 
bile salts. It is then able to passively diffuse into the cells of the small intestines, where 
most of the vitamin D consumed in the diet is absorbed. Intestinal cells contain 
chylomicrons, lipoproteins that transport about 40% of the dietary vitamin D to the 
lymphatic system and blood stream [30]. 
Once vitamin D has been ingested and absorbed, or cutaneously produced and 
diffused through the skin, it enters circulation bound to DBP [30, 49]. Approximately 
60% of vitamin D travels in serum bound to DBP [30]. Albumin and lipoproteins also 
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transport vitamin D in the blood [82]. Vitamin D is primarily carried to the liver, although 
some is taken to extrahepatic tissues by DBP [30]. 
As depicted in Figure 4, vitamin D undergoes two important hydroxylation 
reactions in order to become the biologically active hormonal form. The first of these 
reactions takes place in the mitochondria of liver cells. Mitochondrial cytochrome P450 
enzyme 25-hydroxylase (also called P450C25 or CYP27Al) hydroxylates the vitamin D 
molecule at carbon 25, producing 25-hydroxyvitamin D [25(OH)D]. This molecule is 
biologically inert; however it is the major form in which vitamin D circulates, and its 
serum concentrations peak approximately three hours following UVB exposure [49, 83, 
84]. Although 25-hydroxylase is most abundant in the liver, it is also found in 
extrahepatic tissues such as the lungs, intestines, kidneys and skin, suggesting that 
25(OH)D may also be produced outside of the liver [30, 49]. 
The production of 25(OH)D is regulated, though poorly, by a negative feedback 
mechanism controlled by circulating concentrations of vitamin D, 25(OH)D, and 
1,25(OH)2D. For example, high concentrations of 25(OH)D may inhibit the production of 
25-hydroxylase, thereby preventing further production of 25(OH)D. Also, high 
concentrations of 1,25(OH)2D can inhibit production of la-hydroxylase [responsible for 
the hydroxylation of 25(OH)D to 1,25(OHhD], which then increases 25(OH)D levels in 
the blood (Figure 4) [49, 59]. 25(OH)D is not stored in the liver, and is quickly released 
into circulation, where it has a half-life of approximately three weeks, and travels to the 
kidneys bound to DBP [29, 57]. 
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Inside the kidneys, 25(OH)D undergoes hydroxylation into the biologically active 
metabolite. Once the DBP-25(OH)D complex reaches the kidneys, it is translocated by 
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megalin to the proximal and distal renal tubules [29, 84]. Megalin is a low-density 
lipoprotein receptor on the proximal tubular epithelium of the kidneys, and mediates the 
uptake of DBP-25(OH)D complexes into the tubules [85]. Figure 5 shows that the DBP-
25(OH)D complex binds to the megalin receptors, which mediate entrance into the 
proximal tubule cells. The DBP protein is then degraded in the lysosome, and 25(OH)D is 
carried by intracellular vitamin D binding protein 3 (IDBP-3) to the mitochondria, where 
it undergoes hydroxylation by the cytochrome P450 enzyme la-hydroxylase (also called 
P450Cl or CYP27Bl) to form 1,25(OHhD. Alternatively, some 25(OH)D molecules will 
re-enter circulation and bind to DBP [49, 86, 87]. Although the kidneys are the primary 
site of l,25(OH)2D production, extra-renal production takes place in more than thirty 
tissues, such as placental cells, bone cells, keratinocytes, macrophages, and intestinal cells 
[29,30,49,57]. 
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Figure 5: The role of mega lin and IDBP-3 in the hydroxylation of25(OH)D 
in the kidneys [87]. 
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The regulation of the active vitamin D metabolite, 1,25(OH)2D, is primarily 
controlled by the expression of the la-hydroxylase enzyme, which is stimulated by PTH, 
low plasma calcium concentrations and calcitonin, and inhibited by dietary phosphorus 
and high 1,25(OH)2D concentration [30, 84]. This may be partially explained by the 
ability of PTH to increase the expression of vitamin D receptor (VDR) [88] and calcium-
sensing receptor proteins in the kidneys (responsible for monitoring changes in calcium 
concentrations) [84]. Additionally, high concentrations of 1,25(OHhD down-regulate la-
hydroxylase expression in the kidneys, and increases tubular and intestinal calcium 
absorption [57]. 
Also aiding in the regulation of 1,25(OHhD is the presence of other vitamin D 
metabolites. More than forty other metabolites may be formed when 25(OH)D is 
hydroxylated (by various hydroxylases), all of which are less biologically active than 
1,25(OHhD . For example, 24-hydroxylase can convert 25(OH)D into 24,25-(OH)2D, and 
1,25(OH)2D into 1,24,25-(OH)3D [30, 57]. This enzyme aids in the regulation of 
1,25(OHhD by converting it to the less active 1,24,25(OH)3D form [89], and is expressed 
in most cells, though primarily in the proximal tubule ofthe kidneys [84]. 
1,25(OHhD carries out its hormonal functions on target cells by interacting with 
VDR. From the kidneys, 1,25(OHhD is released into circulation loosely bound to DBP, 
so it may be easily released to the VDR at target tissues. The half-life of 1,25(OHhD is 
approximately 4-6 hours [30], and the half-life of DBP is about 2.5 days [83]. 
Interestingly, although DBP binds 25(OH)D 668 times more strongly than 1,25(OHhD, 
1,25(OHhD binds to VDR 668 times more strongly than 25(OH)D [86]. This ensures the 
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25(OH)D is the primary metabolite in circulation, while 1,25(OH)2D, the biologically 
active form, is able to carry out its functions within target cells. 
Circulating 25(OH)D is the form in which vitamin D is primarily stored. Vitamin D 
can also be stored in adipose tissue, where it has a half-life of approximately eighty days, 
and therefore may be used during winter months or times of low vitamin D production or 
consumption [83]. However, studies have found that obese individuals (body mass index 
(BMI) 2':30 kg/m2) are more likely to have lower serum 25(OH)D concentrations than 
people of normal weight, possibly because vitamin D is sequestered deeper in fat stores, 
making it less available for hydroxylation into 25(OH)D [29, 90-92]. Wortsman and 
colleagues [93] reported more than 50% reduction in bioavailability of cutaneously 
produced vitamin D III obese individuals, but no significant difference in the peak 
circulating vitamin D following supplementation, indicating that the inverse relationship 
is likely due to an inability to maximally absorb cutaneously produced vitamin D. 
2.6 Mechanisms of Action 
1,25(OH)2D may act through both genomIc and non-genomIc pathways when 
carrying out its functions. The 1,25(OHhD-DBP complex is taken up by the cell from 
circulation through diffusion or receptor-mediated endocytosis. Once inside, 1,25(OHhD 
is released from DBP and forms a complex with the vitamin D receptor (VDR). The VDR 
is the 1,25(OHhD receptor, mediating its effect on the target cell [84]. It has been 
hypothesized that a non-genomic 1,25(OHhD-mediated mechanism of action can induce 
a more rapid response from the cell. These mechanisms involve the association of 
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1,25(OH)2D with a membrane VDR that activates signal transductions such as calcium 
transport channels and mitogen-activated protein kinase (MAPK) activation [86, 94]. 
Association with cytoplasmic plasma membrane proteins such as tyrosine kinase receptor 
or G protein coupled receptor [84, 94] may lead to phosphorylations and involvement of 
secondary messengers that carry out rapid responses in the liver, intestines, bone, 
parathyroid and pancreatic ~-cells [30]. 
Genomic pathways take place as the 1,25(OH)2D-VDR complex moves from the 
cytosol into the nucleus [82]. By binding to VDR, 1,25(OHhD is able to regulate the 
transcription rates of more than sixty genes involved in mechanisms such as calcium 
balance, immune regulation and cell differentiation [83]. The binding of 1,25(OHhD to 
VDR leads to conformational changes and phosphorylations that cause the 1,25(OH)2D-
VDR complex to heterodimerize with retinoid X receptor (RXR), a nuclear hormone 
receptor [95]. 
VDR is a member of the nuclear hormone receptor superfamily, and has two zinc 
fingers that allow for interaction with specific vitamin D response elements (VDRE) in 
the promoter regions of various genes [84, 94]. VDREs mediate 1,25(OH)2D -dependent 
gene expression (Wang 2004). Co-modulatory proteins (co-activators or co-repressors) 
also interact with the VDR-RXR complex to enhance or repress gene transcription [30]. 
An example of a co-activator is VDR-interacting protein (DRIP), which recruits RNA 
polymerase II holoenzyme [88], and may also be responsible for unfolding and exposing 
DNA for transcription [82]. These types of mechanisms may potentially take place in any 
of the more than 30 tissues in which nuclear VDRs have been isolated, including bones, 
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intestines, kidneys, lungs, muscle and skin [30]. Biological actions resulting from these 
reactions include calcium homeostasis, mediation of 1,25(OH)2D synthesis and 
breakdown rates, reduction in PTH production and regulation of immune responses [82]. 
2.7 Biological Functions 
There is a large body of evidence for the role for vitamin D in calcium metabolism 
and PTH balance. The association between vitamin D and bone metabolism has also been 
observed in studies of VDR gene polymorphisms and the development of osteoporosis 
[96], rickets [16] and occurrence of hip fractures [61]. However, the involvement of 
vitamin D in the immune processes is less well understood. This section will provide a 
brief review of the relationship between vitamin D and immune reactions, and then 
discuss specific diseases associated with vitamin D deficiency. 
2. 7.1 Involvement of Vitamin D in Immune Processes 
The immunomodulatory role of 1,25(OH)2D is primarily due to the local production 
of the hormone by immune cells such as macrophages, dendritic cells (Des) and activated 
lymphocytes, attenuating adaptive and enhancing innate immune mechanisms [97]. The 
production of VDR in these cells allows 1,25(OHhD to regulate expression of cytokines 
and cell receptors [1]. 
Vitamin D metabolites primarily regulate innate immunity by interacting with 
macrophages, which express I-hydroxylase, the enzyme responsible for converting 
25(OH)D into the biologically active 1,25(OHhD [97]. Macrophages are cells that are 
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commonly exposed to pathogens, recognizing and responding to pathogen-associated 
molecular patterns (PAMPs) on the cell surface of microbes [98]. The PAMPs are 
recognized by pattern recognition receptors (PRRs) on the cell surface of macrophages 
[99]. An important group of PRRs are Toll-like receptors (TLRs), differing in their 
abilities to recognize certain groups of pathogens. The most important vitamin D-
associated innate immune response to infection is the release of the antimicrobial protein 
cathelicidin [100, 101]. In response to pathogenic antigens, macrophages produce the 
biologically active 1,25(OH)2D from circulating 25(OH)D and up-regulate expression of 
cathelicidin, thereby increasing pathogen killing [14]. 
As well as its role in increasing the innate immune reactions, 1,25(OH)2D plays a 
significant role in adaptive immunity. Macrophages and dendritic cells (DC) act as 
antigen presenting cells (APC), presenting antigens to resting T or B lymphocytes and 
activating them [97] (Figure 6). Activated T and B lymphocytes both express VDR, and 
therefore allow for the effects of 1,25(OHhD, such as suppressing the proliferation of B 
and T lymphocytes and reducing immunoglobulin production. The primary target is the T 
helper (Th) cell, which modulates cytokine production [97]. T helper lymphocytes 
differentiate into Thl and Th2 lymphocytes. This polarization of the adaptive immune 
system influences production of various cytokines. Interleukin (IL)-12, produced by 
macrophages and DCs, differentiates naive Th lymphocytes into Thl lymphocytes [98]. 
1,25(OHhD inhibits IL-12 expression by macrophages and DCs [102]. This is consistent 
with the commonly acknowledged role of 1,25(OH)2D in immunosuppression, as the 
hormone has been shown to suppress the Th1 pathway and induce the Th2 pathway, 
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inhibiting inflammatory cytokines such as interferon (IFN)-y, tumour necrosIs factor 
(TNF)-a and IL-2, and increasing development of Th2 cells and corresponding cytokines 
(IL-4, IL-5, IL-lO and IL-13) [1,103]. This type of reaction is beneficial in combating the 
symptoms of some chronic conditions, such as autoimmune or inflammatory diseases 
[104]. However, the mechanism by which it aids in fighting some intracellular pathogens 
has not been as well described. 
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2.7.2 Vitamin D Deficiency and Disease Processes 
As emphasized thus far, vitamin D plays an important role in maintaining several 
biological functions. In absence of sufficient circulating 25(OH)D concentrations, there is 
potential for disease to develop. The following is a brief description of some chronic and 
infectious disease-related implications of vitamin D deficiency. 
2.7.2.1 Chronic Conditions 
One of the primary negative effects of vitamin D deficiency is the decrease in BMD. 
Studies of BMD are commonly carried out among post-menopausal women [105]. For 
example, LeBoff and colleagues [61] found that 96% of women with hip fractures had a 
vitamin D insufficiency «32 nmol/L 25(OH)D concentration), 38% of whom had 
concentrations of circulating 25(OH)D below 9 nmol/L. As well, VDR polymorphisms 
have been found to be associated with vertebral fractures [96]. 
Vitamin D deficiency has also been shown to have an association with various types 
of cancer. For example, certain VDR gene polymorphisms have been associated with an 
increased risk of colon cancer among white individuals [106]. Animal studies have 
suggested that an increase in either exogenous or endogenously-produced vitamin D 
intake may be preventative against colon cancer. This may be attributed to the effect of 
1,25(OH)2D in reducing the inflammatory processes associated with conditions such as 
inflammatory bowel disease and Crohn's disease, which have been shown to be 
predisposing factors for colon cancer [107, 108]. Additionally, a recent meta-analysis 
found that women consuming less than 400 IU/day were more likely to develop breast 
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cancer [109]. Vitamin D deficiency has also been linked to mortality. For example, 
improved vitamin D and calcium nutrition was associated with a reduced rate of all-
cancer mortality [38]. As well, Melamed and colleagues [110] found that vitamin D 
deficiency «45 nmol/L 25(OH)D concentrations) may be associated with a 26% increase 
in the risk of all-cause mortality. 
2.7.2.2 Infectious Diseases 
In contrast with chronic health conditions, the role of vitamin D in infectious 
diseases has not been as widely established, although recent studies have shown 
significant associations between vitamin D and some infectious diseases. For example, 
reduced levels of 25(OH)D and 1,25(OHhD have been found among groups of HN-
positive individuals, compared with HN-negative individuals [111]. In addition, HN-
positive patients are more likely to have osteoporosis and osteopenia, conditions 
commonly associated with vitamin D deficiency and successfully treated with vitamin D 
supplements [112]. Contrary to the previous section discussing the immunosuppressive 
nature of 1,25(OHhD, a small cohort ofHN-infected individuals suggested a relationship 
between high concentrations of 1,25(OHhD and reduced mortality, due to a positive 
association between 1,25(OHhD concentrations and CD4+ T cells counts [111]. This 
relationship is not well described, and remains to be further studied. 
Studies in India have found an association between respiratory tract infections 
among children and insufficient concentrations of circulating 25(OH)D. For example, one 
hospital-based case-control study reported that severe acute lower respiratory infections, 
34 
primarily pneumonia, occurred more frequently among vitamin D deficient children under 
the age of five years [113]. Also infecting the respiratory tract, mycobacteria are 
intracellular organisms commonly found to be affected by vitamin D deficiency. 
1,25(OHhD has been shown to enhance the intracellular killing of Mycobacteria bovis by 
increasing the production of antimicrobial peptides in macrophages, such as cathelicidin 
[101, 114]. The infectious agent most commonly associated with vitamin D deficiency is 
M. tuberculosis. The association between the hormone and bacterium will be the focus of 
the present study, and the following section will provide an introduction to the 
characteristics of the pathogen and its disease process. 
2.8 Tuberculosis 
Before going into detail about the association between vitamin D and tuberculosis, 
the global epidemiology and characteristics ofTB will be briefly discussed. 
2.8.1 Global and Canadian Epidemiology ofTB 
Reported by the WHO to infect approximately one third of the global population 
[4], M. tuberculosis continues to pose a major threat to a large proportion of the world, as 
about nine million new cases of the disease are reported each year (90% of which occur in 
developing countries) [115], and about two million individuals die of the disease [116]. 
Incidence rates of more than 300 new cases per 100,000 population continue to be the 
highest in sub-Saharan African countries, and the lowest incidence rates (0-24/100,000) in 
North America, Western Europe, and Australia [116]. The WHO's Millennium 
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Development Goal 6, to halve the 1990 prevalence and death rates of TB by 2015, may be 
achievable, as most of the world has reported decreasing incidence rates [116]. 
In 2005, 1616 cases (51100,000) of new active and relapsed TB were reported in 
Canada, ranging from an incidence rate of 0.61100,000 in Nova Scotia to 1501100,000 in 
Nunavut. Cumulatively, British Columbia, Ontario and Quebec make up approximately 
75% of the Canadian population, and report 71 % of the total number of reported TB 
cases. The largest proportion of reported cases occurs among individuals aged 25-34 years 
(17% reported cases) and those who are foreign-born (63% reported cases). Canadian-
born Aboriginals make up 19% of total cases reported and Canadian-born non-
Aboriginals 13%. Pulmonary TB is the most common site of diagnosis (57% cases) [117]. 
2.8.2 Characteristics of Mycobacterium tuberculosis 
Mycobacterium tuberculosis was described in 1882 by Robert Koch as the causative 
agent ofTB [118]. The Mycobacterium genus belongs to Group II of the branching, gram-
positive bacterial family Mycobacteriaceae, and consists of more than 85 species [118, 
119]. The three species that most commonly cause human disease are M tuberculosis, M. 
leprae and M ulcerans [120]. 
M tuberculosis are facultative intracellular bacilli with hydrophobic cell walls rich 
in mycolic acids [98]. These complex, branched-chain hydroxyl lipids are characteristic of 
the Mycobacterium genus, and allow for the distinctive staining property of acid-fastness, 
as mycolic acids react with the red carbol fuchsin dye [118]. Sixty percent of the cell wall 
weight is made up of lipids. The resulting low permeability of the cell wall contributes to 
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the natural resistance of the bacilli to regular antibiotics [120]. Individual M tuberculosis 
cells are approximately 0.5 /.lm in diameter and have high-GC genomes. M. tuberculosis 
is an extremely slow-growing organism with a replication time of approximately 30 
hours, taking from days to weeks to produce colonies in artificial cultures [118]. 
2.8.3 Outcomes of M. tuberculosis Infections: Disease, Latency and Reactivation 
Primary exposure to M tuberculosis occurs by the inhalation of droplet nuclei 
containing the bacteria. However, a complex network of predisposing environmental and 
genetic factors determine whether the infection will establish and progress to active TB 
disease (10% of known infections), lay in a dormant state as LTBI (90% of known 
infections), or clear from the body without establishing an infection or leaving any 
detectable immune memory [15, 121]. When active disease develops, it most often occurs 
as pulmonary TB, with extrapulmonary disease manifestations occurring in approximately 
21 % of cases, according to the WHO [122]. If left untreated, those who develop active 
pulmonary disease may stabilize and become asymptomatic carriers, or develop 
disseminated infection that could affect tissues such as the meninges, abdomen, bones and 
joints, and peripheral lymph nodes [123]. Fibrosis and scarring, resulting from caseation, 
are the major causes of clinical disease in pulmonary TB, as normal tissue function is 
impaired and leads to pulmonary difficulties [15,98, 122]. 
As mentioned above, 90% of infected individuals will develop LTBI, the vast 
majority of whom will experience continued latency for the rest of their lives. In this state, 
bacilli can survive for long periods of time without pathological consequences, as long as 
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immune mechanisms continue to function effectively [98, 124]. Otherwise, improper 
granuloma maintenance could lead to rupture and spread of the liquefied caseous center, 
containing tubercle bacilli, to other areas of the lungs, or possible dissemination to other 
parts of the body [121]. This granuloma-contained reservoir of M tuberculosis infection 
has the potential to reactivate and lead to active disease [124]. The majority of reactivated 
cases will present as pulmonary TB with the potential to spread to 10-15 other susceptible 
people [124, 125]. It follows then, that reactivated cases are the main reservoir for TB 
transmission. Approximately 5-10% of individuals with LTBI will reactivate, depending 
on their immunocompetency [122]. Of the approximately nine million cases diagnosed 
each year, a great proportion is due to reactivation [116]. 
Aside from biological factors, there are several social circumstances that contribute 
to the reactivation of LTBI, including a lack of health care, overcrowded living 
conditions, malnutrition and stress. Each of these has the potential to influence the 
progression to disease. For example, stress levels are commonly associated with an 
increased presence of glucocorticoids in the body, which reduce the activation of 
macrophages, thereby stimulating the reactivation of TB in humans and animals [126, 
127]. 
A meta-analysis [128] of 38 studies from 16 countries, exploring the association 
between indoor air pollutions and TB, found that tobacco smoke exposure is another 
factor that is often associated with active TB, the risk of having a positive tuberculin skin 
test (TST) or death from TB. Smoke likely inhibits the normal functions of alveolar 
macrophages, as shown by the reduced phagocytic capabilities, levels of pro-
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inflammatory cytokines, and levels of TNF-a and NO in smokers, compared to non-
smokers. These are all factors that would influence the ability of the immune system to 
eliminate the bacilli upon infection, as well as inhibit the maintenance of the granuloma 
[128]. 
Increased risk of reactivation is also associated with older age. For individuals older 
than 65 years, the chance of a TB diagnosis increases by a factor of four. However, 
interpretation of this fact has to be made with caution, because active disease in the 
elderly can also be caused by increased susceptibility to new infections [129]. 
It has also been established that an increased risk of LTBI reactivation is commonly 
associated with immigration, as this population is more often exposed to risk factors such 
as poverty, need of public health assistance, unemployment and overcrowding [15]. In 
Canada, more than 60% of the TB cases are diagnosed in foreign-born individuals, and 
among them, approximately 41 % reactivate within the first five years, as shown in Figure 
7 [122]. 
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Figure 7: Foreign-born tuberculosis cases in Canada: Time from arrival in 
Canada to diagnosis in years [122] 
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Two studies in Canada used fragment length polymorphism patterns to determine 
the proportion of current TB cases that resulted from remotely acquired (i.e., reactivation) 
versus recent infection. One of these studies, by Kulaga and colleagues [130], 
demonstrated that 82-96% of new active TB cases in Montreal occurred as a result of 
reactivation. The second study used similar methods to determine that foreign-born 
individuals in Vancouver, BC, were strongly associated with having LTBI [131]. 
There are various genetic mutations and polymorphisms that reduce an efficient 
immune response. More than 100 Mendelian disorders have been identified that increase 
susceptibility to infection by reducing IL-12 and IFN -)' production [119]. For example, it 
has been suggested that VDR gene polymorphisms contribute to vitamin D deficiency, by 
reducing effective interactions between 1,25(OH)2D and various immune system 
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mechanisms. In fact, studies have shown an association between vitamin D deficiency and 
TB susceptibility [4]. 
Prevention of LTBI reactivation includes the avoidance or correction of the risk 
factors mentioned above (excluding the genetic predispositions), as well as the use of 
preventative therapies, which consist of pharmaceuticals such as isoniazid for 6-9 months 
or rifampin for four months [132, 133]. However, these drug therapies are avoided unless 
necessary, due to an increased chance of liver injury [133]. As well, vitamin D deficiency 
among individuals with TB suggests that vitamin D may be important in preventing 
reactivation, and may also be a potential form of therapy [11]. 
2.8.4 Cell-Mediated Immunity Diagnosis of Latent Tuberculosis Infection 
Since the focus of the present study is LTBI, providing an in-depth discussion of 
active TB diagnosis is beyond the scope of this thesis. Briefly, upon clinical suspicion, the 
diagnosis of active disease involves a combination of clinical history, sputum smear 
microscopy, bacterial culture and chest radiography [122]. 
As for LTBI diagnosis, a major problem is the lack of a gold standard, which 
prevents from establishing the true global prevalence of LTBI [134]. Diagnosis of latent 
infection is usually determined by the tuberculin skin test (TST), which is based on 
delayed type hypersensitivity (DTH) reaction, to determine if an individual has previously 
been exposed to M tuberculosis. TST uses purified protein derivative (PPD), an antigen 
of M tuberculosis, and its subcutaneous injection evokes a reaction leading to induration 
within 48-72 hours in those who have been previously exposed [98, 135]. When 
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interpreting the results of a TST, it is important to consider more than just size of the 
induration. This is because the technique for measuring the induration in quite variable, 
and greatly depends on factors such as the experience of the health professional carrying 
out the test, presence of HIV infection and age [122]. Consequently, there are three 
dimensions taken into account when evaluating results of a TST. The first is size of the 
induration, usually considered positive when the induration is ~1 0 mm. The second 
dimension is the positive predictive value. TST does not differentiate between LTBI and 
active disease, and the positive predictive value is reduced by the decreased specificity of 
the test. For example, positive TST results often occur in people who have been 
vaccinated by Bacille Calmette-Guerin (BCG) vaccine in the last ten years or have been 
infected by other environmental mycobacteria. For these reasons, a positive TST may not 
always be indicative of a current TB infection [122, 135]. Lastly, the third dimension is 
the risk of developing active TB disease by evaluating risk factors associated with 
reactivation of LTBI [122]. The specificity and sensitivity of TST are 70-85% and 75-
90%, respectively [136]. 
A newer technology for diagnosing LTBI is the interferon-gamma release assays 
(IGRAs). IGRAs are cell-mediated immunity diagnostics, measuring the concentration of 
IFN-y released in response to TB antigens in whole blood. In Canada there are two FDA-
approved commercially available tests based on this principle. They are the T -SPOT. TB® 
(Oxford, Immunotec) and the QuantiFERON-TB Gold® (Cellestis Limited, Australia). 
The present study uses the latter method, specifically the QuantiFERON-TB Gold In-
Tube®, which uses an enzyme-linked immunosorbent assay (ELISA) to detect the 
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presence of IFN-y released by memory T cells upon in vitro stimulation with TB-specific 
antigens, ESAT-6, CFP-1O and TB7.7 [115, 134, 137]. Unlike the TST, IGRA is able to 
distinguish between LTBI and a BeG-vaccinated individual, as these antigens used in the 
assay are absent from all BCG strains [134]. 
In general, IGRAs have shown superior performance to the TST, and are becoming 
the preferred method to assess L TBI. The specificity and sensitivity of the 
QuantiFERON-TB Gold In-Tube® method has been reported as 90-100% and 75-95%, 
respectively [136]. In absence of a gold standard test for LTBI, the IGRA was used to 
determine LTBI status in the present study. 
2.8.5 Immune Response to M. tuberculosis 
Following inhalation of the M tuberculosis bacilli, the pathogen is phagocytosed by 
alveolar macrophages. Various receptors (Figure 8) playa role in the endocytosis of the 
bacteria. Essential to this are the plasma proteins of the complement system's lectin 
pathway [98]. Dectin-1, for example, is a C-type lectin that has been shown to cooperate 
with Toll-like receptor (TLR)-2 in the recognition of M. tuberculosis [4]. As well, 
mannose-binding lectin (MBL) recognizes and opsonises M tuberculosis cell walls at 
mannose residues or N-acetylglucosamine oligo saccharides of cell wall polysaccharides 
[4, 121]. Binding these residues triggers the complement system proteins and proteases to 
initiate phagocytosis through macrophage membrane receptors, such as the mannose 
receptor (MR) [4, 119], and to act as chemoattractants that stimulate inflammation [98]. 
Mannose-binding lectin is part of the collectin family of proteins that also includes 
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surfactant proteins (SP) (also C-type lectins) that maintain alveoli surface tension. Two of 
these, SP-A and SP-D, playa role in the modulation of macrophage-M. tuberculosis 
interactions, leading to the production of reactive nitrogen intermediates (RNI) , lung 
inflammation and antibacterial actions within the macrophage [4]. CR3 is a complement 
receptor that plays a large role in phagocytosis, and in its absence, M. tuberculosis 
phagocytosis by macrophages may be reduced by 70-80% [121]. 
The transmembrane TLR-2 homodimerize or heterodimerize with TLR-6 or TLR-1 
(Figure 8), and act as pattern recognition receptors of lipopeptides, mycolylarabinoglycan-
peptidoglycan complex (cell wall component), lipids and lipoarabinomannan (LAM) (cell 
wall component) of M. tuberculosis. These receptors play critical roles in the 
phagocytosis of M. tuberculosis and the triggering of cytokine production [4, 14]. DC-
SIGN (dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin) is 
a M tuberculosis antigen receptor present primarily on human DCs, although it has also 
been identified on the alveolar macrophage cell surface of individuals with TB, and 
therefore may play an important role in propagating an infection [4] (Figure 8). 
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Figure 8: The interaction of M. tuberculosis and various macrophage cell receptors in the 
modulation of the innate immune reaction to infection [4] 
Once phagocytosed, the anti-mycobacterial functions of the alveolar macrophages 
are induced by the fusion of the phagosome and lysosome. The lysosome, with a pH of 
4.5-5.0, contains acidic hydrolases. The fusion of this organelle with the phagocytosed M. 
tuberculosis results in bacterial degradation in as little as two hours following entrance 
into the macrophage [138]. The phagocytosing of M. tuberculosis by the macrophage 
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sends out a signal that attracts macrophages and DCs to the site of infection. DCs engulf 
or adhere bacteria or bacterial particles and migrate to the lymph nodes, where they 
present antigens to T cells and stimulate their proliferation and migration to the site of 
infection [124]. 
In order to prevent this immune response and remain viable, M. tuberculosis has 
evolved mechanisms to prevent lysosome-phagosome fusion. For example, up-regulating 
production of tryptophan aspartate-containing coat (TACO) proteins by host cells, which 
congregate at the phagosomal membrane following infection and physically prevent 
organelle fusion [138, 139]. Mycobacteria that avoid intracellular degradation multiply, 
leading to the destruction of the macrophage, and releasing tubercle bacilli that attract 
more macrophages to the site of infection to further ingest the bacteria. Alveolar 
macrophages continue to accumulate and mild inflammation develops, although there is 
little tissue damage [98, 121]. 
The ligation of M. tuberculosis or its products to TLRs causes the macrophage to 
produce the pro-inflammatory TNF-a, which activates lymphocytes to produce IFN-y 
[140]. Together with IFN-y, macrophages are activated to produce the mycobacteriocidal 
nitric oxide synthase 2 (NOS2) preventing further replication of M tuberculosis [138, 
141]. Patients with active pulmonary TB have been found to have high levels of exhaled 
NO [138], and NOS2 has also been isolated from the alveolar macrophages of active TB 
patients [142]. 
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The production of IL-12 is strongly induced by mycobacterial infection and secreted 
by macrophages, monocytes, neutrophils and T cells. IL-12 stimulates a strong Thl 
response to infection by inducing the production of IFN-y [4]. Significant reductions in 
bacterial numbers and increases in survival time have been associated with IL-12 
treatment of mice [138]. Cells infected by M tuberculosis produce monocyte 
chemoattractant protein (MCP)-I, which inhibits the production ofIL-12 and IFN-y [143]. 
Lin and colleagues [144] similarly found that an association between active TB and 
increased production ofMCP-l, as circulating CDI4+ immune cells in TB patients have 
been shown to have increased MCP-l production, both systemically and locally. 
Production of certain anti-inflammatory cytokines also plays a role in reducing T-
cell proliferation and function. For example, IL-I0 interferes with host defences against 
M. tuberculosis infection by down-regulating the production of TNF-a by macrophages, 
thereby inhibiting IFN-y production [138]. Murine models deficient in IL-I0 have 
exhibited lower bacterial burden during early infection [121]. As well, production ofIL-6 
and TGF-~ may playa role in suppressing T cell responses and functions [138]. 
Antigen presenting cells (APCs), macrophages and DCs, travel to the lymph nodes 
and present M. tuberculosis antigens to naive T cells [98]. As activation of antigen-
specific CD4+ cells takes place, large amounts of IFN-y and TNF-a are produced, 
assisting the infected macrophage in killing intracellular bacilli [121]. The release of 
chemokines from macrophages and DCs causes more T cells to activate and aggregate to 
wall off infection, forming a Thl-mediated granuloma [98]. As depicted in Figure 9, 
TNF-a plays a major role in the formation and maintenance of the granuloma, influencing 
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cell migration to the site of the M. tuberculosis infection, aggregation and adhesion of 
cells, and continued activation of macrophages [124, 138]. Neutralization of TNF-a has 
been shown to cause disorganized granuloma formation and increased bacterial numbers, 
resulting in 100% mortality in murine models [138]. As well, B cells, Des, endothelial 
cells and fibroblasts migrate and form the granuloma [124] . Macrophages further 
differentiate into epithelioid cells, which form tight linkages with the cell membranes of 
adjacent cells. As well, multiple macrophages can fuse to form giant cells [145]. In the 
center of the granuloma, are the infected macrophages releasing enzymes that cause cell 
lysis and necrosis. Necrosis may occur in an effort to reduce or eliminate M. tuberculosis-
infected macrophages [98]. 
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Figure 9: Immune cells and cytokines important to the maintenance of the granuloma 
during latent tuberculosis infection [124]. 
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2.9 Role of Vitamin D in Immunoregulation of Tuberculosis 
The role of vitamin D in combating M. tuberculosis infections has been observed 
and applied since the 1800s, when phototherapy (developed by Niels Ryberg Finsen in 
1895 [146]) and the consumption of cod liver oil were observed as having curative effects 
for TB patients. The biological mechanisms leading to the health improvement of these 
TB patients have only recently begun to be elucidated [9,147,148]. 
2.9.1 Trends in TB Diagnosis among Immigrants to Non-Endemic TB Regions 
Nowadays, the seasonality of TB diagnosis in some high latitude countries has 
drawn increased attention to the importance of vitamin D in the immune functioning of 
individuals infected with M tuberculosis. A study in the United Kingdom [149] found 
that diagnosis of active TB was more common during early summer than winter months, a 
pattern seen commonly among individuals who had recently immigrated to the UK from 
the Indian subcontinent. This trend may be partially explained by the reduction III 
25(OH)D concentrations that accompames immigration to the UK. The loss of 
endogenous vitamin D production is at its greatest at the end of winter, and reactivation 
and initiation of symptoms, medical attention and diagnosis may be prolonged until 
summer [149]. Among the population of immigrants to the UK, approximately 
80911 00,000 people develop active TB within five years of arrival in London [150]. This 
is also a common trend among immigrants in Canada, who commonly undergo TB 
reactivation at a higher frequency than their fellow citizens in their countries of origin 
[122]. Similarly, recent studies in Spain exploring seasonal trends in TB diagnosis 
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reported a seasonal peak at the end of winter and spnng. This type of trend may be 
explained by several factors such as an increase in indoor exposure to TB during the 
winter months, long spans of time between the onset of symptoms and diagnosis, and a 
reduced cutaneous production of vitamin D during the winter [151]. It seems, however, 
that reduced production of the vitamin is a common denominator in those cases. Vitamin 
D deficiency may have a synergistic combination with other factors, thus increasing 
susceptibility to TB reactivation. 
Another mechanism linking TB reactivation with vitamin D deficiency is VDR gene 
polymorphisms that lead to decreased or negligible circulating levels of the vitamin. In a 
recent study in the UK, TB patients were found to have the lowest 25(OH)D 
concentrations detected, and were ten times more likely to have undetectable 
concentrations of circulating 25(OH)D. Although statistically significant associations 
could not be concluded in this study, VDR gene polymorphisms in combination with 
25(OH)D deficiency and a reduction in antigenic stimuli may have increased the risk of 
LTBI reactivation in this immigrant population [152]. Similar studies in the UK reported 
that serum 25(OH)D concentrations among immigrants from developing countries may 
decrease by a factor of ten following arrival [15]. Recommending supplements to increase 
25(OH)D serum concentrations, therefore, seem like an intuitive solution. However, 
identifying the target concentration remains elusive. Studies among Asian immigrants to 
the UK also demonstrated that decreased immunity to TB was not significantly improved 
by doubling of circulating 25(OH)D by UVB exposure, indicating that higher 
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concentrations of vitamin D intake may be required in order to achieve significantly 
increased levels [153]. 
2.9.2 Latent Tuberculosis Infection and Vitamin D 
Decreased circulating 25(OH)D concentrations among immigrants may be partially 
explained by skin pigmentation. The past 20 years of research have produced studies 
showing a relationship between individuals with darker skin, vitamin D deficiency and 
increased susceptibility to M. tuberculosis infection. Three recent studies have evaluated 
the relationship between LTBI and vitamin D. Firstly, a sample population from Guinea-
Bissau (12°N) on the western coast of Africa did not show a significant association 
between LTBI and vitamin D deficiency. It is important to note, however, that this study 
used TST to determine LTBI status, which may have provided inaccurate results. Due to 
the low specificity of the TST, many of the individuals determined as LTBI positive may 
have been, in fact, negative, resulting in an erroneous lack of statistical association 
between LTBI and serum 25(OH)D concentrations [9]. Secondly, a study among children 
who had immigrated to the UK reported that 86% of children diagnosed in London with 
either TB or LTBI had deficient or insufficient 25(OH)D concentrations, as determined by 
LC-MS/MS [10]. However, this study did not identify if TB/LTBI status was determined 
by TST or IGRA. Lastly, a retrospective study recently examined the 25(OH)D 
concentrations of immigrants from sub-Saharan Africa within various health care settings 
in Australia. Vitamin D deficiency and latent infection with M tuberculosis (as 
determined by IGRA) were found to be strongly associated in this population [8]. The 
results of these studies suggest Vitamin D deficiency an important potential risk factor for 
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TB reactivation, thus continued evaluation and confirmation with more specific testing 
methods and better study designs are needed. 
2.9.3 Genetic Factors 
In addition to the mere availability of vitamin D, genetic differences have been 
proposed as an explanation to the low vitamin D serum levels in certain human groups. In 
fact, multiple VDR gene polymorphisms could have an effect on the host responses to M. 
tuberculosis infection. Time to response to anti-mycobacterial treatment shows a 
significant association with certain VDR gene polymorphisms, suggesting that a change in 
the structure or activity of VDRs could change the host response to active TB. This 
genetic variability may partially account for the specific immune responses to TB present 
in specific ethnic groups [154]. VDR gene polymorphisms may identify a possible genetic 
predisposition to developing TB, although the involvement of specific genotypes is still 
unknown [155]. 
Vitamin D deficiency was recently shown to be a significant risk factor for TB 
reactivation among Gujarati Hindus in the UK. Gujarati Hindus are a primarily vegetarian 
population of immigrants and the researchers considered that low intake of Vitamin D in 
their daily diet may have explained the low serum levels of vitamin D. However, within 
the same population, three VDR gene polymorphisms were associated with the severity of 
vitamin D deficiency and an increased risk of developing active TB. The study concluded 
that the low concentrations of 25(OH)D in the study population were better explained by 
genetic polymorphisms rather than an insufficient intake of vitamin D [121]. 
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2.9.4 Innate Immunity Response to Infection 
1,25(OHhD may carry out its anti-mycobacterial action by regulating the fusion of 
the phagosome and lysosome, preventing the LAM of M. tuberculosis cell wall from 
disrupting the fusion process [13, 156]. Once endocytosed, M tuberculosis must prevent 
degradation by inhibiting the fusion of the phagosome and lysosome within the 
macrophage. As previously mentioned, M tuberculosis avoids phagolysosomal fusion by 
integrating the host cell TACO proteins with its own cholesterol. However, macrophages 
treated with 1,25(OHhD and retinoic acid (RA) have shown a down-regulation of TACO 
gene expression. This is hypothesized to be mediated by the VDRlRXR complex binding 
to the TACO gene promoter [139]. 
Much of the understood interaction between 1,25(OH)2D and M tuberculosis 
infection involves innate immune mechanisms, as macrophages are the primary host cells 
for M tuberculosis. Recognition of the bacilli can potentially involve numerous receptors, 
and trigger multiple pathways within immune cells, as shown in Figure 8. TLR-2 is a 
pattern-recognition receptor that homodimerizes or heterodimerizes with TLR-1 or TLR-6 
on the cell surface of macrophages. The dimerized receptors recognize bacterial antigens 
[4], thereby activating an anti-mycobacterial response in the macrophage [14]. TLRs 
interact with MyD88 (myeloid differentiation protein 88), an adapter molecule 
responsible for initiating intracellular signalling cascade in response to TLR recognition 
of M tuberculosis (Figure 8) [121]. This signalling pathway leads to the upregulation of 
VDR and I-hydroxylase gene expression. I-hydroxylase converts local 25(OH)D into the 
biologically active 1,25(OH)2D, which then binds to the VDR and enters the macrophage 
p 
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nucleus, forming a complex with RXR, and binding VDREs in the promoter region of 
various genes, thereby initiating gene transcription that leads to selective protein synthesis 
(Figures 8 and 10) [14]. 
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Figure 10: The innate immune response to M. tuberculosis 
infection in the presence of 25(OH)D [97] 
Among the proteins up-regulated by 1,25(OHhD, two are of special importance in 
the regulation of mycobacterial infection in the macrophage: NOS2 and anti-microbial 
peptide cathelicidin [4, 14, 124, 157]. NOS2 is responsible for the synthesis of NO, toxic 
to bacteria. Although murine models respond to both acute and chronic M. tuberculosis 
infections with NOS2 production, human macrophages do not produce NOS2 in response 
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to M tuberculosis stimulation in vitro. However, alveolar macrophages of humans with 
active TB express NOS2, suggesting a species-specificity in reaction to M. tuberculosis 
infection [158]. This finding was supported by Martineau and colleagues [157], who 
demonstrated that 1,25(OH)2D only moderately up-regulated NOS2 gene expression in M. 
tuberculosis-stimulated peripheral blood mononuclear cells (PBMC). As well, the 
inhibition of NO formation did not significantly alter the affect of 1,25(OHhD on M. 
tuberculosis-infected cells. This indicated that another protein was having a more 
significant impact on the regulation of M. tuberculosis infection within the macrophage. 
Cathelicidin is an antibacterial peptide produced in response to M. tuberculosis 
infection (Figure 10) of macrophages [14, 159]. This protein is responsible for M 
tuberculosis killing within the phagosomes, by bacterial cell membrane disruption [157]. 
In the same study described above, Martineau and colleagues [157] found that 
1,25(OH)2D strongly regulated expression of the cathelicidin gene (heAP 18), and that the 
addition of synthetic cathelicidin reduced M tuberculosis growth in culture by 75.7%. 
The importance of TLRs and 1,25(OHhD in inducing expression of this antimicrobial 
peptide was shown by Liu and colleagues [14], who found that by inhibiting 1-
hydroxylase (responsible for synthesizing 1,25(OH)2D in the macrophage), the TLR-
induced production of cathelicidin was reduced by 80%, and inhibiting VDR reduced 
cathelicidin production by more than 80%. As well, M tuberculosis death was reduced by 
70%. These findings demonstrate that the TLR-triggered antimicrobial pathway of 
macrophages is dependent on the production and actions of 1,25(OHhD and VDR, and 
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highlights the essential role of 1,25(OH)2D in innate immunity to intracellular bacterial 
pathogens [14). 
In addition to its augmenting effects in the innate immune system by enhancing 
mycobacterial killing in macrophages, vitamin D metabolites have demonstrated 
modulatory effects on the adaptive immune system. However, these effects are said to be 
of immunodepression rather than activation. Experiments show that 1,25(OHhD 
interaction with nuclear VDR suppresses the expression of various cytokines involved in 
the differentiation of naIve T cells (i.e., ThO) into Th1 type cells thereby shifting ThO 
differentiation into Th2 cells. Th1 cells produce pro-inflammatory cytokines (such as 
IFN-y, TNF-a, IL-12, IL-8, IL-6 and IL-10) and a reduction in their production has anti-
inflammatory properties [14, 160). An anti-inflammatory effect may actually have a 
protective role in infectious diseases as it is widely known that uncontrolled inflammation 
may lead to not only more tissue damage but to pathogen spread [12). Controlling 
bacterial spread is of particular importance in TB. 
Since vitamin D production is enhanced by UVB rays during sun exposure, the anti-
inflammatory action of vitamin D is considered an evolutionary protective mechanism 
[161] . This immunosuppresion is compensated though, by the increased production of the 
antibacterial cathelicidin peptide [12, 161). The protective role of vitamin D in TB has 
been demonstrated repeatedly. Numerous studies have shown deficient levels of the 
honnone being strongly associated with active disease [6, 147, 162). Furthennore, other 
studies have also shown that ethnic groups considered at high risk for TB have generally 
lower levels of vitamin D and cathelicidin expression, such as the study by Wang and 
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colleagues [100] who established this difference among African Americans when 
compared to Whites in the United States. The fact that those identified as high risk are 
dark-skinned populations is interesting. Social determinants aside, it may very well be that 
the interference of dark skin in vitamin D synthesis is playing a significant role among 
these populations. 
With all the increasing evidence that vitamin D deficiency is a major a risk factor 
for TB reactivation, it can be hypothesized that the vitamin somehow plays a vital role in 
the immune maintenance and integrity of the granuloma, thus preventing latent infection 
from becoming active. The WHO data affirms that one third of the world population 
harbours latent TB infection and that the majority of the 8-9 million TB clinical cases per 
year are due to reactivation of a latent infection [116]. Preventing reactivation is 
paramount to achieving the MDG 6 by 2015 [163]. With this in mind the scientific 
community is currently engaged in the creation of new vaccines to prevent TB infection 
and new and better drugs to treat and cure it. At the same time, alternative approaches 
including immunomodulators are being investigated. Among these, the potential of 
vitamin D as a low-cost and easily manageable risk factor for developing active TB has 
been received with much optimism among the scientific and clinical community [157]. 
The aim of the present study is to contribute to the understanding of the potential role of 
vitamin D in latent TB infection in a population from a medium-TB burden country. 
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CHAPTER THREE: METHODOLOGY 
The purpose of this study was to determine frequency of vitamin D deficiency as a 
risk factor for latent TB reactivation among Mexican migrant workers in the Niagara 
Region. This study was an extension of a larger study that was initiated in March 2007 as 
the graduate project of Angela Duarte (supervised by Dr. A. Sanchez) in collaboration 
with the University of Puebla in Mexico, entitled "Preliminary Epidemiological Study of 
Latent Tuberculosis in Mexican Agricultural Workers in the Niagara Region, Canada", 
and funded by the ClHR. Duarte's study set out to assess the prevalence of LTBl, and 
associated risk factors for infection, in a population of Mexican agricultural workers in the 
Niagara Region of Ontario, Canada. 
Various farms in the Niagara Region were contacted before workers could be 
approached for participation. Within each farm agreeing to participate, individuals 
providing free and informed consent were enrolled. Participation included completion of a 
questionnaire, TST and extraction of a blood sample for the lGRA. Questionnaires 
contained questions regarding details of enrolment, living conditions in Canada, socio-
demographic data in Mexico, and TB knowledge and history. Questionnaires were 
distributed and explained in Spanish. LTBl was assessed by TST as a screening test, and 
an lGRA was performed as a confirmatory test. TSTs (Tubersol®, A vantis Pasteur 
Limited) were performed by registered nurses, and trained phlebotomists took the blood 
samples for the IGRA (QuantiFERON-TB Gold In-Tube®, Cellestis Limited, Australia) 
(see Appendix II for QuantiFERON-TB Gold In-Tube® technique). Blood samples were 
consistently taken in the evening, following work hours during August 2007. This 
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preliminary study on latent TB conformed to the research ethics standards outlined in the 
Tri-Council Policy Statement [164] and received Research Ethics Board approval from 
Brock University, File #DUARTE06-288. Participants gave consent and provided a blood 
sample to be tested for levels of vitamin D, which was analyzed using a code number, 
centrifuged and the serum stored at -20°C for use at a later date. These samples were 
tested for circulating 25(OH)D concentrations in the present study. 
3.1 Research Objectives 
3.1.1 General Research Objective 
To determine the frequency of vitamin D deficiency, a risk factor for LTBI 
reactivation, among healthy individuals with known status for latent TB infection. 
3.1.2 Specific Research Objectives 
Objective 1. Using a widely accepted radioimmunoassay, determine the serum 25(OH)D 
concentrations among healthy individuals from a TB-endemic country, and establish the 
proportion of individuals with sufficient, insufficient and deficient vitamin D status. 
Objective 2. Determine if a statistically significant difference existed between the 
25(OH)D concentrations of males and females, as well as between age categories (defined 
in a later section). As well, determine if a statistically significant difference existed 
between the vitamin D status (sufficiency, insufficiency and deficiency) of males and 
females, as well as between age categories. 
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Objective 3. Analyze what variables are independent predictors of 25(OH)D 
concentrations and vitamin D status, including age, sex, number of years enrolled in the 
Seasonal Agricultural Workers Program (SA WP), number of months in Canada during the 
present season, alcohol consumption, latitude of Mexican state of origin, and completion 
of primary school. 
Objective 4. Establish 25(OH)D concentrations and vitamin D status of individuals in the 
LTBI-negative and LTBI-positive groups, and determine if a significant difference existed 
between the 25(OH)D concentrations and vitamin D status between LTBI-negative and 
LTBI-positive groups. 
Objective 5. Determine if serum 25(OH)D concentrations were statistically correlated 
with interferon-gamma concentrations previously determined, in the overall sample and 
among LTBI-positive participants. 
3.2 Research Design 
This study was a cross-sectional analysis of circulating 25(OH)D concentrations 
among a convemence sample of 92 Mexican workers within the Niagara Region' s 
agricultural industry. 
Circulating concentrations of 25(OH)D were quantified using a radioimmunoassay 
(RIA), allowing for the determination of vitamin D sufficiency, insufficiency and 
deficiency based on previously determined cut-points. These allowed for the 
determination of the point prevalence of vitamin D deficiency and insufficiency. 
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The vitamin D analysis will be performed in a blind fashion with respect to the 
LTBI status of individual participants. 
3.3 Study Funding 
The present study received funding through a Brock University Advancement Fund, 
awarded to Dr. Paul LeBlanc as a Principal investigator and Dr. Ana Sanchez as a co-
investigator. Partial funding was also obtained from the Canadian Institutes of Health 
Research (CIHR). 
3.4 Ethical Considerations 
Informed consent was obtained from all research participants in the summer of 
2007, as was approval from Brock University's Research Ethics Board. Consent forms 
were distributed and signed by participants following the explanation of the nature of the 
research project, the study's procedures, potential risks and benefits associated with the 
study, procedures by which confidentiality will be maintained and assurance of the 
voluntary nature of participants ' involvement. A modification to file number 
DUARTE06-288 adding Dr. LeBlanc and Timna Merion as researchers was submitted 
and accepted by the REB of Brock University, allowing access to anonymous data. 
The present study involved the manipulation of previously collected serum samples 
and anonymized questionnaire data, and therefore presented no physical or other risks to 
the participants. Continued confidentiality of participants' data was ensured. 
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3.5 Biosafety and Radiation Safety 
Biosafety and radiation safety training seSSIOns were carried out by Brock 
University's Environment, Health and Safety Office before beginning laboratory 
procedures. This was followed by on-site radiation training by Dr. P. LeBlanc in his 
laboratory, which consisted of proper handling and storage of radioactive materials, use of 
the gamma radiation counter, record keeping and clean-up procedures. 
Initial blood and serum sample manipulation was performed in Dr. A. Sanchez's 
laboratory, accredited Biosafety Level II. Radioimmunoassay techniques were performed 
in a designated radioactivity bench at Dr. Paul LeBlanc's laboratory, by Timna Merion, 
under the supervision of thesis advisors, Dr. A. Sanchez and Dr. P. LeBlanc. Lab coats 
and disposable gloves were worn while handling biological and radioactive materials. All 
radioactive materials were carried out on a designated radiation lab bench. 
3.6 Laboratory Methodology: 25-Hydroxyvitamin D 1251 Radioimmunoassay 
3.6.1 Background and Principle of the Assay 
After entering circulation, vitamin D is metabolized into many forms, primarily 
25(OH)D. Since this is the most abundant form in which vitamin D is stored in the body, 
this is the metabolite for which this assay is testing [165]. This is the metabolite most 
commonly used to determine vitamin D status [21, 58, 166-170]. 
The DiaSorin 25(OH)D RIA procedure consists of two steps. First, 25(OH)D and 
other hydroxylated metabolites are rapidly extracted from the serum samples. Second, the 
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samples are assayed using an equilibrium RIA method, which uses an antibody specific to 
25(OH)D[165]. 
3.6.2 Assay Technique 
3.6.2.1 Extraction Procedure 
Samples and standards were ali quoted in duplicates. 12 X 75 mm disposable glass 
tubes were set up and labelled for calibrators, controls and research participants samples. 
500 IlL of acetonitrile were added to each tube using a pipette. 50 IlL of the calibrator, 
control or patient were added to the respective tube by placing the pipette tip below the 
surface of the acetonitrile and slowly adding the contents. Once all samples were 
completed, each tube was vortexed for 10 seconds. The tubes were all centrifuged at 1200 
X g (g = (1118 X 10-8) (radius in cm) (rpmi) for 10 minutes at 20-2YC. 
25 IlL aliquots of supernatant were pipetted in duplicates into labelled 12 X 75 mm 
disposable glass tubes. Supernatants were assayed as indicated by the Assay Procedure, 
outlined below. 
3.6.2.2 Assay Procedure 
This procedure was carried out on a designated radiation laboratory bench, and all 
pipettes used were labelled as radioactive. All reagents and samples were equilibrated to 
room temperature (up to a temperature of 25°C). Disposable glass tubes were labelled and 
set up in duplicates in the order of "Total Counts", "NSB", "Calibrator 0" to "Calibrator 
5", "Controls" and "Unknown Samples". 
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Reagents were added as follows: 
1. Total Count tubes: 
• 50 ~L of 125I 25(OH)D tracer 
• 1.0 mL of NSB/Addition buffer 
2. Non-specific binding tubes (NSB): 
• 25 ~L of Extracted 0 calibrator 
• 50 ~L of 125I 25(OH)D tracer 
• 1.0 mL ofNSB/Addition buffer 
3. Calibrators, controls, and unknown samples: 
• 25 ~L of calibrator, control, or unknown sample (extracted) 
• 50 ~L of 125I 25(OH)D tracer 
• 1.0 mL of25(OH)D antiserum 
Each tube was gently vortexed to avoid foaming, and incubated for 90 (± 10) 
minutes at 20-25°C. 
DAG precipitating complex was poured into a beaker and stined with a stir bar 
before and during use. 500 ~L DAG was added to all tubes, except the "Total Count" 
tubes. All tubes were mixed well and incubated for 20-25 minutes at 20-25°C. 
500 ~L of NSBI Addition buffer was added to all tubes, except the "Total Count" 
tubes, and vortexed gently to avoid splashing (although the tubes were mixed well). All 
tubes were centrifuged for 20 minutes at 20-25°C at 1800 X g, except the "Total Count" 
tubes. 
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Supernatants were decanted (except for the "Total Count" tubes) by inverting each 
tube into an appropriate waste container, and then each tube was inverted and placed in a 
rack over absorbent paper for 2-3 minutes. Each tube was gently blotted to remove all 
liquid. 
3.6.2.3 Radiation Measurement 
A Gamma scintillation counter (Wallac Wizard 1470 Automatic Gamma Counter, 
model #1056 1349) was used to quantify the concentrations of 25(OH)D in the serum 
samples. All the tubes were placed in a gamma scintillation counter in groups of ten, and 
counted for at least 1 minute. Results of the standards were plotted to construct a standard 
curve and printed. 
3.7 Cut Points Selected to Define Vitamin D Levels 
Based on the literature [61-67, 171], cut points will be defined as follows: 
Vitamin D sufficiency: 2:80 nmol/L 
Vitamin D insufficiency: <80 nmol/L, >37.5 nmollL 
Vitamin D deficiency: :S37.5 nmollL 
3.8 Determination of L TBI - Summary of the Technique and Interpretation 
LTBI was determined by the interferon-gamma release assay (IGRA) , 
QuantiFERON-TB Gold In-Tube® (Cellestis Limited), which incorporates proteins early 
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secretory antigenic target (ESAT-6), culture filtrate antigen (CFP-I0) and TB7.7. This test 
quantifies the IFN-y released by T lymphocytes in the whole heparinised blood of 
individuals, following stimulation with the M tuberculosis proteins listed above. The 
antigens used in this test are not present in any strain of BCG, and therefore are not likely 
to produce a reaction in individuals who have been immunized, but are uninfected. This 
test is therefore an indicator of LTBI and a supporting test for the diagnosis of active 
TB[I72]. 
First, whole blood was collected directly into three specialized tubes, including a 
Nil Control tube, TB Antigen tube (containing the protein cocktail), and a Mitogen 
Control tube, and incubated at 3TC. Secondly, the tubes were centrifuged and the plasma 
was removed. An ELISA was used to quantify the IFN-y response. The antigen tube was 
considered to have a positive IFN-y response when it is significantly higher than the IFN-
y response of the Nil tube[I72]. 
3.9 Predictors of Vitamin D Status 
Factors identified in the literature as having an association with circulating 
25(OH)D concentrations have include age [34, 53, 167, 173], skin pigmentation [152, 
153,174], diet [175], sun protection [49], latitude [153,174] and season [167, 176]. There 
has also been some analysis of the association between vitamin D deficiency and alcohol 
consumption [177] and education level [9, 178, 179]. The current study included the 
following independent predictors of vitamin D deficiency and 25(OH)D concentration: 
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• Age 
• Sex 
• Number of years with in SA WP 
• Length of stay in Canada 
• Latitude of Mexican state of origin 
• Levels of completed education 
• Alcohol consumption 
Data for these variables were taken from the questionnaire, with exception of two, 
number of months in Canada and latitude of Mexican state of origin, which were 
calculated from data provided in the participants' questionnaires. Number of months in 
Canada was calculated from month of arrival to month at which blood samples were taken 
(month of arrival was provided). Participants provided their state of origin on the 
questionnaire, from which the approximate latitude was determined [180] from the state 
of origin provided by participants in the questionnaire. Age remained as a continuous 
variable, but was also described in terms of categories for the purpose of showing age 
distributions. Age was categorized into 20-29, 30-39, 40-49 and 2:50 years. Selection of 
potential predictors of 25(OH)D concentration was limited by the questionnaire content. 
Therefore risk factors such as skin pigmentation, diet and sun protection measures could 
not be included. 
3.10 Data Analysis 
Objective 1. Means and standard deviations (SD) were used to describe the serum 
25(OH)D concentrations of the overall population, as well stratified by sex and age 
68 
categories. Frequencies and percentages described the vitamin D status (deficiency, 
insufficiency and sufficiency) of the overall population, as well stratified by sex and age. 
Objective 2. A t-test was used to determine if there was a significant difference between 
the 25(OH)D concentrations of males and females, and an ANOVA was used to 
determine if a significant difference existed between age categories. Fisher's exact tests 
were used to determine if vitamin D status significantly differed between sex or age 
categories. 
Objective 3. In order to assess which variables were independent predictors of 25(OH)D 
concentration and vitamin D status, a multiple linear regression (MLR) and logistic 
regression were performed, respectively. Backward selection was used to determine 
inclusion in the regression models, in which variables with a p value 2:0.20 were 
eliminated from the models [181]. Vitamin D deficiency was the reference group in the 
logistic regression. 
Objective 4. Descriptive statistics of the serum 25(OH)D concentrations stratified by 
L TBI status was presented as means and standard deviations, and vitamin D status 
stratified by LTBI status was presented as frequencies and percentages. A t-test was used 
to determine if 25(OH)D concentration was significantly different between LTBI-negative 
and LTBI-positive participants. A Fisher's exact test was used to determine if vitamin D 
status significantly differed between LTBI-negative and LTBI-negative participants. 
Objective 5. A Spearman correlation was used to assess if there was a significant 
correlation between 25(OH)D and IFN-y concentrations within the overall population and 
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within the LTBI-positive group. The strength of the association was determined by the 
correlation coefficient. 
Statistical analysis of the data was carried out using the software package SAS 
version 9.1 (SAS Institute, Cary NC, USA). Significance was determined by 95% 
confidence intervals and a p value of p<O.05 for all analyses. Assumptions for the 
statistical analyses were checked and met. Serum 25(OH)D concentrations were log 
transformed in order to meet the assumption of normal distribution for linear regression, 
and back-transformed by taking the antilog before interpretation of the results. 
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CHAPTER 4: RESULTS 
Of the 92 serum samples collected by Duarte from Mexican agricultural workers in 
the Niagara Region during August of 2007, 87 were included in the present study. The 
samples had been stored at _20DC in plastic Eppendorf tubes during the interim, and 
assayed for concentrations of the vitamin D metabolite 2S(OH)D between January and 
February of 2009 using a 2S(OH)D 1251 radioimmunoassay (RIA) kit purchased from 
DiaSorin®. The results of five serum samples were not included in the present study. 
Three of these were not included because they contained an insufficient volume of serum 
for the assay to be carried out (SOIlL was required). The results of the remaining two 
participants were not included because their coefficient of variation (CV) percentages did 
not meet predetermined cut-offs of 10%. Repeat analyses of these two samples could not 
be carried out as planned due to an insufficient volume of serum remaining. 
Training and preparation for use of the DiaSorin® 2S(OH)D RIA to assay the serum 
samples took place regularly over a period of three months. Training consisted of three 
stages before samples from the present study were handled and assayed. Firstly, training 
workshops for both radiation and biosafety were completed at Brock University. 
Secondly, samples of the researchers and other volunteers from Brock University were 
collected and assayed. This exercise was used to gain experience and comfort with the 
assay procedure, and address potentially problematic steps in the procedural process. 
Thirdly, 46 serum anonymized samples from Puebla, Mexico, collected during the study 
led by Pezzat and collaborators in June 2008, were assayed in triplicate using the RIA 
kits. These samples were collected as part of a complementary study, and results were 
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sent back to the Mexican researchers in January 2009 for their decoding and 
interpretation. Consistently low CV percentages «10%) for intra-assay variability among 
the Puebla specimens, which were all tested in triplicate, conferred confidence that the use 
of duplicate samples, as recommended by the manufacturer, may be used thereafter. 
25(OH)D concentrations were measured with a Gamma Radiation Counter and 
output data was produced in count per minute (CPM). The CPM of the calibrators, total 
counts and NSB buffer were used to generate a calibration curve in Microsoft Excel® 
using the procedure and formulas provided by DiaSorin®. A new set of calibrators were 
assayed and new calibration curve produced for each set of samples. The 25(OH)D 
concentrations were calculated from the calibration curve equation, yielding a 
concentration in ng/mL, which was subsequently converted to nmol/L by multiplying by a 
factor of2.496. 
nmol 25(OH)D = 2.496 x ng 25(OH)D 
L mL 
Demographic characteristics and tuberculosis-related data were obtained from the 
surveys which were carried out as part of the Duarte study. All variables were entered into 
SAS Version 9.1 for statistical analysis. 
4.1 Description of the Research Participants 
As previously stated, 87 (94.6%) of the original 92 study participants were included 
in the present study, including 68 (78.2%) males and 19 (21.8%) females. The average 
age of the participants was 38.0 (± 9.14) years, with ages ranging from 22-65 years. 
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Among male participants, the average age was 39.1 (± 9.27) years, ranging from 22-65 
years, and the average female age was younger at 34.1 (± 7.65) years, ranging from 24-49 
years. As depicted in Table 4, 78.2% of the sample was made up of male participants, 
while 21.8% was made up of females. The average time of participation in the SA WP 
program was 6.3 years (±5.68) (6.8 years (±5.8) for males and 4.4 years (±4.0) for 
females). The latitude of origin for each participant varied between 16°-25°N, majority of 
whom originate from approximately 19°N (61%) and 21°N (15%). Other demographic 
characteristics such as age distributions, number of years of SA WP enrolment, Mexican 
state of origin, type of housing in Mexico, level of completed education and the number 
of months in Canada are presented below in Table 4. Fourteen out of the 87 (16.1 %) 
participants were LTBI positive, as determined by the QuantiFERON-TB Gold In-tube® 
IFNy release assay. 
Table 4: Demographic characteristics from a sample of 87 Mexican agricultural 
workers in the Niagara Region, stratified by sex 
Age (years) 20-29 10 (14.7) 7 (36.8) 17 (19.5) 
30 - 39 29 (42.7) 6 (31.6) 35 (40.2) 
40-49 20 (29.4) 6 (31.6) 26 (29.9) 
2:50 9 (13.2) 0(0) 9 (10.3) 
Number of years 1-5 37 (54.4) 12 (63.2) 49 (56.3) 
enrolled with 6-10 17 (25.0) 6 (31.6) 23 (26.4) 
SAWP 11-15 4 (5.9) 1 (5.3) 5 (5.8) 
16-20 7 (10.3) 0(0) 7 (8.1) 
21-25 3 (4.4) 0(0) 3 (3.5) 
Type of housing Type I 48 (71.6) 13 (72.2) 61 (71.8) 
in Mexicot Type II 15 (22.4) 3 (16.7) 18 (21.2) 
Type III 3 (4.5) 2(11.1) 5 (5.9) 
Type IV 1 (1.5) 0(0) 1 (1.2) 
Level of None 10 (14.7) 1 (5.3) 11 (12.6) 
education Primary 31 (45.6) 4 (21.1) 35 (40.7) 
completed Secondary 24 (35 .3) 10 (52.6) 34 (39.5) 
Technical 3 (4.4) 3 (15.8) 6 (7.0) 
Other 0(0) 1 (5.3) 1 (1.2) 
Length of stay in 2 2 (3 .0) 6 (31.6) 8 (9.3) 
Canada (months) 3 0(0) 0(0) 0(0) 
4 19 (28.4) 9 (47.4) 28 (32.6) 
5 37 (55.2) 3 (15.8) 40 (46.5) 
6 9 (13.4) 1 (5.3) 10(11.6) 
'j' Type of housing is classified according to the presence of certain household amenities, including indoor 
potable water, indoor flushing toilet, indoor electricity, and cement or tiled floors. Type I: All four 
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characteristics are present; Type II: Any three characteristics are present; Type III: Any two characteristics 
are present; Type IV: One characteristic is present 
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4.2 Vitamin D Status 
4.2.1 25(OH)D Concentrations in the Study Population 
The mean 25(OH)D concentration of all participants was 74.9 nmol/L (±20.1), 
ranging 31. 9-149.7 nmol/L. Seven participants had concentrations 2: 100 nmol/L. Mean 
25(OH)D concentration in this population did not differ by sex or age classifications, as 
shown in table 5. 
Table 5: 25(OH)D concentration of 
Mexican agricultural workers classified by 
sex and age category (n=87) 
Male 76.6 (±20.S) 
Female 6S.S (±16.3) 
P = 0.16 
20-29 76.0 (±3.57) 
30-39 6S.4 (±IS.61) 
40-49 77.S (±24.79) 
2.50 78.3 (±14.4S) 
p = 0.26 
Nonnality of the 25(OH)D concentration distribution was tested usmg the 
Anderson-Darling test for nonnality, which yielded a p value of 0.005, indicating that 
25(OH)D concentrations were not nonnally distributed. In order to achieve a nonnal 
distribution, the concentrations were log transfonned prior to analysis, for which the 
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Anderson-Darling test yielded a p value of O.OS, indicating normal distribution. In order to 
satisfy the assumption of normal distribution required for Student's t-test and linear 
regressions, the log of the 25(OH)D concentrations was utilized for analysis, and then 
converted back from the log value to the antilog. A Student's t-test was performed in 
order to find if a significant difference existed between the mean 25(OH)D concentrations 
of males and females. The t-test indicated that there was no significant difference between 
the 25(OH)D concentrations of males and females (p=0.16). Using an ANOV A it was 
determined that 25(OH)D concentrations did not differ significantly among the age 
categories (p=0.26). 
4.2.2 Categorizing the Vitamin D Status of the Study Participants 
As previously stated, the 25(OH)D concentrations were categorized into sufficiency 
(2:S0 nmoI/L), insufficiency «SO nmollL) and deficiency (:::;37.5 nmollL). Table 6 shows 
the frequency distributions of each of these categories. 
Table 6: Vitamin D status of Mexican 
agricultural workers classified as deficiency, 
insufficiency and deficiency (n=S7) 
Deficiency (:::;37.5 nmol/L) 2 (2.3) 
Insufficiency «80 nmol/L) 59 (67.8) 
Sufficiency (~80 nmollL) 26 (29.9) 
Since the deficiency category only contained two participants, it was merged with 
the sufficiency category to create a dichotomous vitamin D status variable. Therefore, 
70.1 % of participants were classified as having as an insufficient 25(OH)D concentration 
76 
«80 nmol/L) and 29.9% of participants were classified as having a sufficient 
concentration (2:80 nmollL). 
Table 7 shows the frequency of vitamin D insufficiency and sufficiency in the 
population, stratified by sex. One of the cells had a frequency of less than 5, which does 
not meet the requirement of a Chi-squared test. Instead, a Fisher's exact test was 
performed in order to evaluate if a statistical association existed between vitamin D status 
(i.e. sufficiency versus insufficiency) and sex. The p value computed by the Fisher's exact 
test was p=0.16, indicating that there was no significant relationship between vitamin D 
status and sex in this study population. 
Table 7: Vitamin D insufficiency and sufficiency of 
Mexican agricultural workers, stratified by sex (n=87) 
Insufficient «80 nmollL) 45 (66.2) 16 (84.2) 
Sufficient (2:80 nmollL) 23 (33.8) 3 (15.8) 
p = 0.16 
Table 8 shows vitamin D status stratified by age categories. A Fisher's exact test 
was used to evaluate the relationship between the two variables. It was determined that 
there was no significant relationship between vitamin D status and age (p=0.36). 
Table 8: Vitamin D status of Mexican agricultural workers stratified by 
age (years) 
Insuffi ci ency 8 (9.2) 20 (23.0) 23 (26.4) 10 (11.5) 
Sufficiency 1 (1.2) 6 (6.9) 12 (13.8) 7 (8.1) 
p = 0.36 
4.3 Predicting 2S(OH)D Concentration and Vitamin D Status 
4.3.1 Identifying Predictors of Vitamin D Status 
77 
Logistic regression was carried out in order to assess the predictive effect of specific 
factors on vitamin D status (sufficiencylinsufficiency). Potential predictor variables were 
taken from published peer-reviewed literature, including sex, number of years enrolled 
with SA WP, length of stay in Canada (current growing season), latitude of Mexican state 
of origin, education level completed, and alcohol consumption. Variables were removed 
from the model by backward elimination selection [181], and inclusion was determined 
by a significance value of p<0.20 [181]. An effect of collinearity was found between age 
and number of years enrolled in the SA WP, and therefore the inclusion of number of 
years of enrolment acts as a proxy for age. Table 9 shows the results of the analysis, 
including the odds ratios for sex, number of years in the SA WP, length of stay in Canada 
(current growing season) and completion of primary school. A significant association was 
not found for latitude of Mexican state of origin and alcohol consumption. 
Table 9: Covariates oflogistic regression predicting vitamin D status of 
Mexican agricultural workers# 
Number of years enrolled with the SAWP 
Length of stay in Canada (months) 
Completion of primary schoolt 
t Female sex was compared to male sex 
0.06 (0.01, 0.37) 
0.86 (0.76, 0.98) 
0.33 (0.16, 0.68) 
2.60 (0.83, 8.17) 
t Completion of primary school was compared to no schooling completion 
0.02 
0.003 
0.10 
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# Eliminated variables (p>0.20): latitude of Mexican state of origin, alcohol consumption 
Females were 94% more likely to be insufficient than men. As well, with each year 
increase in age, individuals were 14% more likely to have insufficient concentrations of 
25(OH)D. Similarly, within each growing season, for each additional month in Canada, 
individuals are 67% more likely to have an insufficient vitamin D status. The OR of 
primary school completion was not significant in a 95% confidence interval. In order of 
elimination from the model, alcohol consumption and latitude of the state of origin were 
not found to be significant independent predictors of vitamin D status, with p values of 
0.42 and 0.30, respectively. 
4.3.2 Identifying Predictors of 25(OH)D Concentrations 
In order to assess which demographic factors are independent predictors of 
25(OH)D concentration, a multiple linear regression (MLR) was performed. Predictor 
variables were included based on the current literature, and removed from the model in a 
backward selection procedure [181]. Variables with a p-value 2:0.20 were eliminated from 
the model [181] . The number of years enrolled with the SA WP was used as a proxy for 
age, due to an effect of collinearity between the two variables. Potential predictor 
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variables analyzed included: sex, number of years enrolled with the SA WP, length of stay 
in Canada during the current growing season, latitude of Mexican state of origin, 
education level completed, and alcohol consumption. Table 10 shows the results of the 
MLR for each of demographic factors that were included in the model, which included 
sex, number of years enrolled in the SA WP, length of stay in Canada (current growing 
season) and education completed. A significant association was not found for alcohol 
consumption or latitude of Mexican state of origin. Completion of secondary and 
technical schools did not yield significant associations; therefore completion of primary 
school was compared to no schooling completion. 
Table 10: Covariates of the multiple linear regression predicting 
25(OH)D concentrations of Mexican agricultural workers# 
Number of years enrolled in SA WP -1.03 (-1.05, -1.00) 0.02 
Length of stay in Canada (months) -1.21 (-1.38, -1.06) 0.007 
+ Completion of primary schooP 1.18 (-1.09,1.52) 0.195 
t Female sex was compared to male sex 
! Completion of primary school was compared to no schooling completion 
# Eliminated variables (p>0.20): latitude of Mexican state of origin, 
alcohol consumption 
The 25(OH)D concentration of females was 1.56 nmollL less than males. Each 
additional year enrolled in SA WP resulted in a 1.03 nmol/L reduction in 25(OH)D 
concentration. As well, for every additional month in Canada (in the current growing 
season) the concentration of 25(OH)D was reduced by 1.21 nmol/L. Primary school 
completion was not a significant predictor of 25(OH)D concentration within a 95% 
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confidence interval. The R2 of the model was 0.1949, and therefore 19.49% of the 
variance in 25(OH)D concentration can be predicted by the model. In order of 
elimination, excluded variable and corresponding p-values were latitude of Mexican state 
of origin (p=0.77) and alcohol consumption (p=0.67). 
4.4 Relationship between Vitamin D Status and L TBI Status 
Of the 87 research participants, 14 (16.1 %) were determined L TBI positive by the 
QFT-G IT assay (Duarte et aI, 2009; submitted for pUblication). A Fisher's exact test was 
performed, and determined that there was no significant relationship between vitamin D 
status and LTBI status in this study population (p=0.54) (Table 11). One of the 
participants had an indeterminate LTBI status, and was not included in this analysis. 
Table 11: Vitamin D insufficiency and sufficiency of Mexican 
agricultural workers, stratified by LTBI status (n=86) t 
Insufficiency 11 (78.6) 49 (68.1) 
Sufficiency 3 (21.4) 23 (31.9) 
p = 0.54 
T One person not included due to an indeterminate L TBI status 
Within the LTBI negative group, the mean 25(OH)D concentration was 75.1 nmol/L 
(±21.3). The mean 25(OH)D concentration for the LTBI positive group was 74.1 nmollL 
(±12.3). A Student's t-test determined that no significant difference existed between the 
25(OH)D concentrations ofLTBI positive and negative individuals (p=0.89). 
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4.5 Association between 25(OH)D Concentration and IFN-y Concentration 
To determine if a linear relationship existed between concentrations of 25(OH)D 
and IFN-y, a correlation analysis was performed (n=87). Due to the fact that neither 
variable was normally distributed, a Spearman correlation was carried out. The correlation 
coefficient obtained was 0.14 (p=0.19), and therefore not statistically significant. A 
Spearman correlation was also carried out between concentrations of 25(OH)D and IFN-y 
of the LTBI positive participants (n=14). This yielded a correlation coefficient of 0.53 
(p<0.05), indicating a moderate correlation between the 25(OH)D and IFN-y 
concentrations among individuals who are positive for LTBI (Figure 11). 
120 .----~-~------ -------- ---
~ 100 
-15 • E 
..s 80 • c: 
• t • 0 I ·z ... 
• l!! • 
• 
..... 60 - -- ----c: 
Q.I 
v 
c: 
0 
u 40 ---C • 
::E: 
0 
in 20 
N 
o T 
o 5 10 15 20 25 
IFN-V Concentration (lU!mL) released in reponse to TS antigens 
Figure 11: Spearman correlation between 25(OH)D concentrations and IFN-y release by 
effector T cells of LTBI-positive participants 
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CHAPTER 5: DISCUSSION 
The present study has focused on determining the vitamin D status of Mexican 
migrant workers in the Niagara Region, with the particular aim of evaluating the 
relationship with LTBI. The WHO's estimate that one third of the world is latently 
infected with M. tuberculosis [116], and research suggesting vitamin D deficiency may 
lead to LTBI reactivation, highlight the importance of defining the relationship between 
these two conditions. 
The role of vitamin D metabolites in the regulation of calcium homeostasis has long 
been acknowledged. These metabolites, 25(OH)D and 1,25(OH)2D, respectively function 
as the primary storage and biologically active form of vitamin D [59]. More recently, 
production of 1,25(OHhD had been shown to be more ubiquitously distributed throughout 
the body, and involved in the upregulation of the gene coding for cathelicidin, an anti-
mycobacterial protein [14]. 
Many LTBI reactivation studies have been carried out among foreign-born 
populations from TB-endemic, tropical or subtropical regions that have re-Iocated in 
developed regions at higher latitudes, where sun exposure is reduced, leading to reduced 
production of vitamin D in the skin. In Canada and the UK, since the onset of TB 
symptoms and diagnosis take place most often within the first five years following 
immigration, it has been theorized that vitamin D deficiency due to reduced sun exposure 
may play an immunoregulatory role in reactivation of LTBI [122, 150]. Although a 
definitive association has not been established for the relationship between vitamin D 
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deficiency and LTBI reactivation, it remains a potential risk factor for reactivation and 
progression to active TB. Further study of vitamin D status may contribute to the 
understanding of L TBI in migrant populations. 
5.1 Characteristics of Research Participants 
Mexican agricultural workers have been commg to work in Canada with the 
Seasonal Agricultural Work Program (SAWP) since 1974 [182], with women entering the 
program in 1989 [183]. Employment criteria and recruitment processes require that 
SA WP participants are at least 18 years of age, have agricultural experience and a 
minimum third grade education, and undergo a medical examination to ensure Canadian 
health requirements [182]. This suggests that the demographic characteristics of the 
population of Mexican workers are reasonably uniform. Age ranges of the Mexican 
workers are reported by the Consulate General of Mexico as being 22-45 years [182]; 
however the study population in Niagara revealed an age range of 22-65 years (mean 38 
years). On average, the number of years of schooling among Mexican workers in Canada 
has been found to be 7.7 years, which is equivalent to the national mean of Mexico [184]. 
All but 12.6% of the participants in the present study met the minimum education 
requirement. 
In Canada the vast majority of SA WP workers are men, with women making up 
only 3% of this population [184], but in the present study women comprised 21.8% of the 
sample of SA WP workers in the Niagara Region. The proportion of female workers in 
Niagara has not been previously reported in publications. 
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Currently, the SAWP includes workers from each of the 32 Mexican states; 
however the present study population includes participants from 18 centrally located 
states. This is consistent with the literature reporting that up to 70% of the SA WP 
participants reside in the six central states, probably due to the fact that recruitment and 
promotional activities are centered in Mexico City [184]. 
Generally, the SAWP workers begin arriving in January, and can remain in Canada 
for a maximum of eight months [182]. At the time of blood sample collection, the study 
participants had been in Canada for a range of2-6 months, arriving between February and 
June. Almost half of the individuals arrived in March, with only 9.3% arriving in June. 
This differs somewhat from the majority of Mexican SA WP workers, most of whom 
arrive during the summer months [182]. The average work period each year for the 
SA WP workers is about 4.9 months, with approximately 73% returning to work in 
Canada from season-to-season [184]. Overall, the group of Mexican agricultural workers 
involved in the present study can be considered representative of the population of 
Mexican migrant workers who come to Canada as part ofthe SAWP. 
5.2 Vitamin D Status of the Study PopUlation 
Using a 1251 radioimmunoassay (RIA), the overall 25(OH)D concentration of the 
study population was determined to be 74.9 nmol/L, with concentration means of 68.8 
nmoliL and 76.6 nmol/L in females and males, respectively. The prevalences of vitamin D 
insufficiency and sufficiency were 70.1 % and 29.9%, respectively. Global 25(OH)D 
concentrations of healthy adults are generally considered to be insufficient. A meta-
analysis carried out by Hagenau and colleagues [174] reported an overall mean of 54 
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nmol/L (HPLC and RIA), although studies from African and South American countries 
were less available than from North America and Europe. 
Since regional characteristics have a fundamental impact on determining vitamin D 
status, it is important to evaluate the vitamin D status of Canadians. Baseline circulating 
25(OH)D concentration of a representative sample of healthy Canadian citizens, to date, 
has not been established. Currently, results from the Canadian Health Measures Survey 
(CHMS) (2007-2009), a survey that measures health indicators and physical activity 
levels in a representative sample of Canadians, are being aggregated in order to provide a 
better understanding of the national prevalence of vitamin D deficiency [185, 186]. The 
availability of this data will fill an important gap because there are a limited number of 
studies attempting to establish the vitamin D status of healthy adult Canadians. Vieth and 
colleagues [187] reported that healthy adults (not consuming vitamin D supplements) 
working indoors in Toronto (43°N latitude) had winter and summer 25(OH)D 
concentrations (RIA) of 40.7 and 46.7 nmol/L, respectively. Similarly, Rucker and 
colleagues [34] evaluated the 25(OH)D concentrations (RIA) of healthy adults (not 
consuming vitamin D supplements) in Calgary (51 oN latitude). Average 25(OH)D 
concentration was 57 nmollL during winter, and 72 nmollL during summer months when 
UVB exposure was at its peak. These studies highlight the effect of latitude and season 
on cutaneous vitamin D production in Canadians, which is likely reflected in the vitamin 
D status of Mexican workers as well. 
Regions above 42°N latitude have no UVB exposure during winter months, and 
therefore no cutaneous production of vitamin D at this time. The latitude of the central 
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Mexican states from which most of the study participants originated is approximately 
200N [105]. Therefore, workers may have lower 25(OH)D concentrations while residing 
in Niagara than while in Mexico. Acknowledging that the long hours working outdoors 
may compensate for the strength of the Mexican sun, effect of long hours are likely 
minimized by the workers' apparel of long sleeves, pants and hats [188]. Currently, there 
is no published data reporting the circulating 25(OH)D concentrations of Mexican 
agricultural workers in Canada, nor those of healthy adults living in Mexico [189-191]. 
Two studies carried out among post-menopausal women in Mexico found average 
25(OH)D concentrations of approximately 65 nmollL, 67% with insufficient 
concentrations «75 nmol/L) (RIA and competitive protein binding assay) [105, 192]. 
Although this study population is not comparable to the present study, it is interesting to 
note that despite the differing age groups these concentrations are similar to those of 
women in the present study. This may be attributed to Mexico's latitude and resulting 
increase in UVB exposure. Therefore adult Mexicans may likely be vitamin D replete and 
have fairly homogeneous circulating 25(OH)D concentrations [189]. In the present study, 
serum 25(OH)D concentration did not significantly differ between age categories, nor did 
prevalence of vitamin D insufficiency have a statistically significant relationship with age 
category. This trend has been previously reported [170, 193, 194], although some studies 
report a decreasing 25(OH)D concentration with increasing age [92, 195] as expected due 
to reduced cutaneous vitamin D3 production with increasing age [53]. 
Recently, access to unpublished serum 25(OH)D RIA results from 46 Mexican 
family members of SA WP workers from Puebla were found to have a mean circulating 
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25(OH)D concentration of 68.1nmo1/L (65.6 nmol/L in females and 76.9 nmol/L in 
males), 78% with insufficient vitamin D status. The overall mean 25(OH)D concentration 
was likely much lower due to the larger proportion of female participants (78%), 
compared to the present study (21.8%) (Pezzat et aI, unpublished data). The present study 
did not find significantly different 25(OH)D concentration between males and females, 
which is supported by some literature (Vecino-Vecino 2005; Kudlacek 2003), although 
others have found significantly higher concentrations in males than females (Scragg 2008; 
Skull 2008). These differences are usually associated with religious affiliation that 
requires women to be fully covered. There is no biologically identified explanation for 
differences between males and females, which are likely related to lifestyle or 
occupational characteristics. 
5.3 Predicting 25(OH)D Concentrations 
According to various studies, there are multiple factors that can be used to predict 
vitamin D status, including age [173], skin pigmentation [174], sun exposure [49], diet 
[175], latitude [174], alcohol consumption [177] and season [167]. For immigrants to 
higher latitudes, skin pigmentation [152, 153], latitude [153], length of time in the host 
country [196] and season [176] play important roles in determining vitamin D status. 
In the study, females were more likely to have lower 25(OH)D concentrations than 
males. The effect of sex on prediction of 25(OH)D concentration has been previously 
described in immigrant populations. Skull and colleagues [196] aimed to establish the 
prevalence and risk factors for vitamin D deficiency among immigrants from East Africa, 
finding that women had higher odds of deficiency than males. As most of these 
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participants were of the Muslim religion, this may have been caused by a lack of sun 
exposure due to protective clothing. In the present study, this relationship between men 
and women may be due to the types of jobs given to men and women, as women generally 
undertook indoor jobs, such packing [188]. Factors such as the younger age of women and 
fewer numbers of months in Canada were controlled for in this model. 
As expected, an increased number of years involved in the SA WP, as a proxy for 
age, was a significant predictor of reduced 25(OH)D concentration. As previously 
mentioned, increased age has been associated with a reduced capacity to produce 7-DHC 
in the epidermis, thereby reducing the amount of vitamin D produced in response to UVB 
exposure [53]. The age of participants was correlated with the number of years involved 
in the program, as older age indicates an increased opportunity to return. This result was 
mirrored in the logistic regression, which showed a greater likelihood of insufficiency 
with each year of returned enrolment and therefore each year increase in age. Rucker [34] 
found that increased age was significantly associated with lower 25(OH)D concentrations, 
regardless of season. Looker [167] found the same pattern for 25(OH)D concentration, 
however the effect of age was weaker during the winter months than summer. 
In the present study, a longer stay in Canada predicted lower 25(OH)D 
concentrations and insufficiency. This trend was likely due to two factors. Firstly, the 
length of time spent at higher latitude than Mexico, and therefore at a reduced UVB 
exposure, may have reduced vitamin D production in the skin. This relationship has been 
previously observed in immigrant populations. Skull [196] observed in a cross-sectional 
study that an increased number of months in Australia predicted vitamin D deficiency 
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among East African immigrants, with the likelihood of vitamin D deficiency increasing 
fivefold after two years. There is a lag of approximately two months before an observed 
reduction of circulating 25(OH)D, due to its slow mobilization (along with vitamin D) 
from adipose tissues, which act as storage sites [92]. Secondly, since samples were taken 
in summer, those who have been longer in Canada may have experienced some time 
where UVB exposure was not possible, while those who spent fewer months in Canada 
arrived later, and therefore did not experience a period without UVB. As previously 
mentioned, at 42°N latitude UVB does not reach the Earth's surface between November 
and February [34], yielding an effect of seasonality on vitamin D status. This effect of 
seasonality was recently described by Moreno-Reyes [193], who found the peak 25(OH)D 
concentration of immigrants to Brussels during July-September to be significantly higher 
than the concentration measured in January-March or April-June, indicating that during 
winter months there is limited UVB exposure. 
5.4 Vitamin D and L TBI Status 
Since majority of TB cases in developed regions are attributed to reactivation of 
LTBI, factors associated with immigration are thought to playa role [122]. A severe 
vitamin D deficiency «10 nmol/L [152] and <25 nmol/L [8]) has previously been 
associated with high prevalence of active TB among foreign-born individuals living at 
higher latitudes. Establishing the vitamin D status of individuals with and without L TBI 
may provide insight into immune status or potential for reactivation. The present study did 
not find a significant difference between the serum 25(OH)D concentrations of LTBI 
positive (74.1 nmollL) and negative individuals (75.1 nmol/L), and similarly no 
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relationship between vitamin D status and LTBI status was found. However, it should be 
noted that the present study did not have sufficient power, and a larger sample size would 
provide a more accurate description of these relationships. The relationships between 
either vitamin D status or 2S(OH)D concentration and LTBI status have not been well 
described in the literature. 
A handful of retrospective studies have attempted to investigate the relationship 
between these factors. Two studies did not find differing 2S(OH)D concentrations by 
LTBI status, while one identified a significant difference. Firstly, a UK clinic found 86% 
vitamin D insufficiency «7Snmol/L, LC-MS/MS) among children with TB and LTBI, 
with 79% insufficiency identified in LTBI positive children alone. TB/LTBI status did not 
have a significant effect on the vitamin D status of these children [10); however, LTBI 
diagnostic methods were not identified and there was no control group (LTBI negative 
participants) with which to compare 2S(OH)D concentrations. Secondly, vitamin D status 
was compared between TB patients and healthy controls in West Africa, with healthy 
controls including LTBI positive and negative individuals (TST). Similarly to the present 
study, vitamin D deficiency (LC-MS/MS) was not significantly different between LTBI 
positive and negative groups [9]. However, the low specificity and large number of false 
positives of the TST may have yielded inaccurate results. Lastly, differences in serum 
2S(OH)D concentrations between LTBI positive and negative individuals (lORA) were 
shown among African immigrants in Australia [8]. This final study did not specify the 
type or consistency of vitamin D assay. All included records were taken from one 
hospital, indicating that the same vitamin D assay was utilized, though these findings 
must be interpreted with caution. These studies provide insight into the lack of 
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consistency and accuracy in determining the potential role of vitamin D in L TBI, as well 
as highlight the importance of studying this relationship in immigrant populations. 
Differences in these samples would need to be followed longitudinally to determine if low 
25(OH)D concentrations resulted in reactivation. 
While still considered insufficient, participants III the present study were not 
severely vitamin D deficient. This may be explained by the fact that the participants 
worked long hours outdoors during summer months when samples were collected. 
However, the previously mentioned work attire of long sleeves, pants and hats for 
avoidance of scratches and chemicals [188], likely also prevented large increases in 
cutaneous vitamin D production. Immigrants to non-endemic TB regions normally 
experience a wintertime reduction in vitamin D production, which is associated with a 
subsequent late spring or early summer increase in TB diagnosis due to L TBI reactivation 
[149, 151]. The workers' continuous return to Mexico at summer's end provides them 
with UVB exposure unavailable during Canadian winters, thereby avoiding long periods 
without cutaneous vitamin D production. 
Vitamin D metabolites are known immune regulators that inhibit the Thl pro-
inflammatory reactions of the adaptive immune system, some of which are important for 
preventing LTBI reactivation by maintaining the integrity of the granuloma. This may 
seem paradoxical, but the down-regulation of circulating pro-inflammatory cytokines 
likely prevents potentially detrimental effects to lung or other tissues. The granuloma 
provides the host with a physical barrier within which inflammatory cytokines are 
concentrated. In this setting, pro-inflammatory cells such as T cells and macrophages are 
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brought into close proximity with M tuberculosis [124], allowing for intracellular 
bacterial killing by anti-mycobacterial cathelicidin. With an increase from 23 nmollL to 
78 nmol/L, Liu and colleagues [14] observed a 2.5 fold increase in cathelicidin mRNA 
production in human monocytes cultured in human serum. As well, this reaction was 
dependent on the presence of a TLR211 ligand, such M. tuberculosis. Therefore 
circulating 25(OH)D may ensure local production of 1,25(OH)2D, and therefore 
cathelicidin, in macrophages infected by M. tuberculosis in the granuloma during L TBI. 
The local production of the active metabolite 1,25(OH)2D in immune cells has also 
been observed by Lin and colleagues [197] in non-human primates. In cynomolgus 
macaques, calcification of tuberculous granulomas indicated the local production of 
1,25(OH)2D, suggesting that the 1,25(OHhD concentration inside the granuloma differs 
from the 1,25(OHhD production in other tissues. Therefore Th1 depression may only be 
enough to prevent over-production of 1,25(OHhD that would lead to hypercalcemia and 
potential toxicity outside of the granuloma. This may partly explain the results of the 
present study showing no significant difference between circulating 25(OH)D 
concentrations of LTBI positive and negative participants, as each of these groups are 
clinically healthy, indicating that vitamin D metabolite concentrations are maintained in 
balance with immune reactions. 
5.5 25(OH)D and IFN-y Concentrations 
Among LTBI positive individuals, there was a moderate, positive correlation 
between serum 25(OH)D concentrations and IFN-y concentrations (released by T cells in 
response to M. tuberculosis antigens). This correlation did not exist when all participants 
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were included (i.e., LTBI positives and negatives), because LTBI negative individuals 
lacked previous exposure to M tuberculosis antigens required for the stimulated release 
of IFN-y from peripheral effector T cells. There are various mechanisms by which vitamin 
D metabolites interact with the immune system, some of which are better understood than 
others. 
A precise interpretation of differing M tuberculosis-stimulated IFN-y production 
has yet to be established. Recent M tuberculosis infections generally result in a greater 
secretion of IFN-y. Effector cells that have been recently exposed to M tuberculosis 
antigens in vivo are likely to respond to re-exposure with rapid IFN-y release [198]. 
Therefore, workers presenting with higher IFN-y concentrations may have been more 
recently exposed. This could be due to antigenic stimulus by primary infection, re-
exposure while in Mexico or granulomatous breakdown that was later contained. As well, 
higher IFN-y concentration may indicate incipient active TB among recently infected 
individuals [199]. Therefore, if any of these individuals were recently infected, this could 
suggest future reactivation. This same relationship has not been reported in individuals 
known to have a long time latent infection. 
The immune mechanisms involved in this relationship are not yet fully understood. 
1,25(OHhD down-regulates transcription and secretion of Th1cytokines IFN-y, IL-12 and 
TNF-a in M. tuberculosis-infected macrophages, DCs, T cells and PBMC in culture [102, 
157]. As previously stated, Th1 cytokines are important for maintaining the granuloma, 
and therefore preventing reactivation [200, 201]. This down-regulation of IFN-y by 
1,25(OH)2D seems to contradict the findings of the present study and the established 
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association between vitamin D deficiency and active TB. However, 25(OH)D IS the 
inactive precursor of 1,25(OHhD, and is not an indicator of 1,25(OH)2D activity. 
This positive correlation may be indicative of a chance relationship between 
circulating 25(OH)D concentrations and lFN-y release by effector T cells. Firstly, there 
was not sufficient power in this Spearman correlation to accept its outcome. Secondly, 
upon further consideration it was concluded that carrying out an analysis of these two 
variables had numerous weaknesses. For example, the in vitro nature of the lFN-y release 
assay meant that a large amount of TB antigen was used to induce a hyper-response from 
the effector T cells. Under natural conditions, effector T cells would not be exposed to 
such a high concentration of TB antigens. As well, the presence of TB antigen may have 
overridden any down-regulation of lFN-y by 1,25(OHhD. Lastly, it must be 
acknowledged that two different samples were utilized to determine the lFN-y and 
25(OH)D concentrations. The 25(OH)D concentrations were measured directly from 
serum samples, while the lFN-y release was measured following stimulation of T cells in 
whole blood. It is possible that circulating 25(OH)D or 1,25(OH)2D could have been 
affected by the sample manipulation during the lORA. Since 25(OH)D concentration was 
not measured following completion of the lORA, this cannot be disregarded. 
Overall, the average 25(OH)D concentration of this population, while below the 
determined cut-point of sufficiency does not indicate severe deficiency. As none of the 
workers showed signs of LTBl reactivation, concentrations of 25(OH)D slightly lower 
than optimal may still influence immunological protection in the management of L TBI. 
This study highlights the need to gain a better understanding of vitamin D status of 
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migrant workers as it relates to LTBI reactivation, and underscores the importance of 
nutritional health promotion in this population. 
5.6 Study Strengths 
The 1251 RIA (DiaSorin Inc., Stillwater, MN) utilized in the study is the most 
commonly used assay for quantifying circulating 25(OH)D concentrations in human 
serum. It is the assay for which other assays are calibrated, and its use allows for the 
comparison of 25(OH)D concentrations and vitamin D insufficiency prevalence values 
with many published studies. It provides results in a relatively short amount of time and 
for a larger number of serum samples. The 25(OH)D RIA also has 100% cross-reactivity 
between the 25(OH)D2 and 25(OH)D3 vitamin D metabolites, and therefore provides a 
more accurate measurement of the total circulating 25(OH)D than some other assays. 
Determination of LTBI status (by Duarte) was carried out with an IGRA 
(QuantiFERON Inc., Cellestis Ltd., Australia) and used as a confirmatory test for TST 
results. The TST required by the Public Health Agency of Canada is not always indicative 
of a current TB infection, as it is affected by Bacille Calmette-Guerin (BCG) vaccination 
and other environmental mycobacteria. In absence of a gold standard test for L TBI, the 
IGRA is the preferred method of determining LTBI positivity, as it is able to distinguish 
between LTBI and a BCG-vaccinated individual and has higher specificity and sensitivity 
than the TST. 
This was the first study to report the vitamin D status of Mexican migrant workers 
in Canada's Niagara Region, and results can be generalized to Mexican workers in other 
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parts of Canada. As well, in the absence of vitamin D data for healthy Mexican adults, 
results from this study may provide an indication of the vitamin D status of healthy 
Mexican adults. 
In the absence of any other vitamin D data in this population, the cross-sectional 
design of the study allowed for the relatively fast collection of preliminary data. This 
provided a snapshot of the prevalence of vitamin D insufficiency and related 
characteristics, and how they relate to L TBI status. 
5.7 Study Limitations 
This study made use of the previously completed survey (developed by Duarte and 
Sanchez) that focused on risk factors for LTBI. Therefore some important predictors of 
vitamin D status were unavailable for analysis, such as skin pigmentation, diet and 
nutrition, type of work done by the participants (indoor versus outdoor) and a 
measurement for sun protection. The inclusion of these variables would have allowed for 
a more in-depth analysis of predictors of vitamin D insufficiency. However, some of these 
variables, while important risk factors for insufficiency, may add further limitations to the 
study. Inclusion of diet and nutrition variables to ascertain dietary intake of vitamin D 
would have to be very specific. Dietary intake relies on participants' ability to recall past 
actions in detail, and may be difficult to analyze due to differing fortification systems and 
vitamin D content of fish. As well, the type of work and sun protection behaviours may 
change from day to day and so would have to be carefully evaluated. 
97 
This was a convemence sample, and therefore not randomly selected. Potential 
participants could only be approached among farms agreeing to participate and within a 
limited timeframe at the end of the summer season. While convenience sampling tends to 
reduce the generalizability of results, the nature of some of the characteristics being 
measured in this study, such as LTBI status and serum 25(OH)D concentrations, may not 
be strongly influenced by this limitation. In addition, the small sample size of the study 
limited the number of individuals that could be analyzed for LTBI positivity or vitamin D 
deficiency. 
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5.8 Future Research 
5.8.1 Conducting Longitudinal Studies 
In order to provide an indication of the potential role of vitamin D metabolites in 
LTBI reactivation, a longitudinal study must be carried out in which the 25(OH)D 
concentrations of LTBI positive individuals (and uninfected controls) are monitored over 
a span of at least five years. 25(OH)D concentrations would be evaluated seasonally. This 
would likely be carried out among immigrants to Canada from TB-endemic regions, as 
reactivation is likely to occur within the first five years of arriving in the host country, and 
active TB is likely due to reactivation of latent infection. This would allow for a more 
accurate association between LTBI status and vitamin D status, as well as the potential of 
vitamin D deficiency (and severity of deficiency) to influence reactivation of latent 
infection. This knowledge may be beneficial to public health agencies monitoring and 
perhaps predicting the levels of reactivation in Canada. 
5.8.2 Assessment of Fluctuation ofCytokine Profile in LTBI Positive Individuals 
The cytokine profile of LTBI positive individuals, including concentrations of Thl 
cytokines TNF-a and IFN-y, and how they fluctuate have not yet been examined. Further 
analysis of these cytokines, important to the maintenance of the granuloma during latent 
infection, may help to evaluate if there is a shift in immune balance over time and in 
relation to vitamin D status, especially 25(OH)D concentrations. While 1,25(OH)2D has 
been shown to inhibit the production of these cytokines, there is currently no known 
association between concentrations of these cytokines and 25(OH)D, the metabolite 
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measured in the determination of vitamin D status and the measure of exposure and 
supply of the nutrient to target tissues. This may suggest or lead to some other as yet 
undefined immune interactions in place. 
5.9 Conclusions 
This study added to two important and growing bodies of literature. Firstly, this 
study provided circulating 2S(OH)D concentrations of healthy adult Mexican men and 
women living in Canada, which have not been reported before. Secondly, publications 
focusing on the relationship between LTBI status and vitamin D insufficiency are few. 
This is the first time this relationship was evaluated in a group of migrant workers from a 
TB-endemic sub-tropical region temporary employed and residing in a non-endemic 
regIOn. 
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The majority of Mexican migrant workers were vitamin D insufficient, but very few 
were severely deficient, indicating the vitamin D status may not have been greatly 
reduced during the temporary stay in Canada. This was likely due to participants' return 
to the lower latitudes of Mexico following Niagara's growing season, and their 
subsequent avoidance of Canadian vitamin D winters. 
No significant difference in vitamin D status between LTBI positive and negative 
individuals, and the lack of LTBI reactivation, indicated that although the 2S(OH)D 
concentrations were lower than optimal, they were likely high enough to maintain 
immunological protection against LTBI reactivation. Determining if a critical 2S(OH)D 
concentration for reactivation exists remains a challenge and a potential focus of future 
prospective studies. 
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Brock University Research Ethics Board (REB) 
Requestfor Ethics Cle",rance of a Revision or Modification to an Ongoing 
Application to Conduct Research with Human Participants 
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Please refer t.o Brock University Research Ethics Guidelines, found at http://www.hr.ocku.caircsearchserviccs prior 
t.o completi.on and submissi.on .of this applicati.on. Ify.ou have questions about.or require assistance with the 
completi.on of lhis fOIro, please contact the Research Ethics Office at (905) 688-5550 ext. 3035, .or rebraibrocku.ca. 
Once e.omp1c:te, please rerum this f.onn with aU acc.ompanying material t.o MacKenzie Chown D250A. 
SECTION A - GENERAL INFORMATION 
1. Title ofthe Research Project: Preliminary epidemiological study of tuberculosis in Mexican 
agricultural workers in the Niagara Region, Canada. 
2. Principal Investigator: Angela Duarte File Number: DUARTE 06·288 
Department: Community Health Sciences Email: angela.duarte@brocku.ca 
3. Faculty Supervisor: Dr. Ana Sanchez Department: Community Hea.lth Sciences 
Email: ana.sanchez@brocku.ca Phone Ext.: 4388 
4. Original Approval Date: March 15, 2007 Anticipated Closing Date: December 30,2008 
SECTION B - MODIFICATIONS/REVISIONS 
5. Pr.ovide a brief description .of,and explanati.on f.or, the revisi.on(s) or m.odificati.on(s) requested to your 
applicati.on that preViOUsly received ethics clearance. If the revisi.on(s) is (are) to a questionnaire or 
interview prot.ocol with previous ethics clearance, submit the entire d.ocument and highlight the 
sections that are revised or added. A complete copy .of any new measure(s) or scale(s) must be 
attached f.or ethics review. 
We w.ould like t.o. include Dr. Paul LeBlancfr.om the Department of Community Health Sciences as a co-
investigat.or 5.0 that the proposed vitamin D analyses can be performed. Dr. LeBlanc was awarded a Brock 
University Advancement Fund to examine the levels .of pr.o-vitamin D and their associaU.on with cellular 
immunity against tuberculosis in a sample of healthy Mexican agriculture w.orkers in the Niagara Region. This 
modificati.on t.o the previ.ously accepted REB will allow for a release .of funds and f.or the research to proceed. 
We would also like t.o include Timna Merion as a MSc graduate student whose research pr.oject will include 
the examination .of vitamin D levels in the af.orementioned sample. Timna will learn the lab techniques and 
perform the assays under Dr Leblanc's and Sanchez supervision. 
6. a) Do the revised pr.ocedures .outlined above require and change(s) t.o the Inf.ormed Letter/C.onsent 
Fonn currently in use and that previ.ously received ethics clearance? [ 1 Yes [X] No 
Office of R.eseareh Services' BrOCk University. 500 Glenridge Ave· Sl. Catharines. ON· L2S 3A 1 
- 1 -
b) 11 yes, briefly describe these changes. Attach a copy of the revised Information Letter/Consent 
Form and highlight the revised sections. 
SECTION C - SIGNATURES 
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IfINe respectfully request ethics approval of the modifications/revisions described above. All modified 
Documents and procedures have been submitted for REB review and approval. 
Signature of Principal Investigator Date 
Signature of Faculty Supervisor Date 
'Office Use Only 
The Modification request as described above to an ongoing project involving human participants has 
been reviewed and received ethics clearance. 
Chair, Research Ethics Board Date 
Office of Research Services' Brock University· 500 Glenridge Ave· SI. Catharines, ON· l 2S 3A 1 
-2-
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APPENDIX II: QuantiFERON-TB Gold In-Tube Procedure 
Background and Principle of the Assay 
During M tuberculosis infection, mycobacterial antigens will trigger the response 
of cell-mediated immunity (CMI), including the release of the IFN-y cytokine. This test 
incorporates proteins (ESA T -6, CFP-I0 and TB7. 7) that simulate mycobacterial peptides. 
Individuals who are infected with M. tuberculosis have T lymphocytes in their blood that 
will react to these proteins by releasing IFN-y, which is then quantified. The antigens used 
in this test are not present in any strain of BCG, and therefore is not likely to produce a 
reaction in individuals who have been immunized, but are uninfected. This test is 
therefore an indicator of LTBI and a supporting test for the diagnosis of active TB. In 
absence of active TB, positive results of this test could indicate a LTBI. However, other 
Mycobacteria (ie. M. kansasii, M. szulgai and M marinum) may also yield positive test 
results [172]. 
Whole blood is collected directly into three specialized tubes, including a Nil 
Control tube, TB Antigen tube (containing the protein cocktail), and a Mitogen Control 
tube that controls for proper blood processing techniques and unknown immune status of 
participants. For example, a low IFN-y response «0.5 IU/mL) in the Mitogen tube and 
negative response in the TB Antigen tube indicates an indeterminate response. A TB 
Antigen tube is considered to have a positive IFN-y response when it is significantly 
higher than the IFN-y response of the Nil tube. The IFN-y response of the Nil tube is 
120 
subtracted from that of the TB Antigen and Mitogen tubes, in order to adjust for non-
specific IFN-y present in the blood [172]. 
Assay Technique 
Stage One: Blood sample collection and storage (This stage was completed in 
2007as a component of Angela Duarte's Master's thesis project). Using 70% ethanol, a 
certified phlebotomist disinfected the arm of the participant from which the blood sample 
was taken. A tourniquet was applied 3-4 inches above the puncture site, and 5 mL of 
blood extracted from the larger median cubital, basilica or cephalic veins into a vacutainer 
tube without anticoagulant. Samples were stored and transported to Brock University in 
an ice box. At the laboratory in Brock University, the samples were centrifuged and stored 
at _20DC until they were used. 
Stage Two: Human IFN-y ELISA. Before use, plasma samples and reagents were 
equilibrated to room temperature (22°C ± 5°C) for approximately 60 minutes. Strips that 
were not utilized were removed from the microplate frame, and stored in the refrigerator 
in a sealed foil pouch. The freeze dried Kit Standard was reconstituted using 0.25 mL 
distilled water (as indicated on the Standard vial), and gently mixed. A 1 in 4 dilution 
series of IFN-y in Green Diluent was produced using the reconstituted Kit Standard. 
Standards were assayed in duplicates. Two sets of four tubes will be labelled: "s 1", "S2", 
"S3" and "S4", to each of which 150 )lL of Green Diluent was added. 150 )lL of the Kit 
Standard was added to the tubes labelled "s 1", and thoroughly mixed. 50 )lL of the 
contents of "s 1" were then transferred to "S2", and thoroughly mixed. 50 )lL of the 
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contents of "S2" were be transferred to "S3", and thoroughly mixed. "S4" contained only 
Green Diluent, which was the zero standard. The concentrations of the standards "Sl", 
"S2", "S3" and "S4" were then be 4.0, 1.0,0.25 and 0 IU/mL, respectively. 
Freeze dried Conjugate lOOX was reconstituted with 0.3 mL of distilled water, and 
gently mixed. Working Strength Conjugate was produced by diluting the reconstituted 
Conjugate 100X Concentrate in Green Diluent, according to Table 1, and mixed gently. 
Table 1: Conjugate Preparation [172] 
NUMBER VOLUME OF VOLUME OF 
OF STRIPS CONJUGATE GREEN DILUENT 
lOOX CONCENTRATE 
2 10lAL 1.0mL 
3 15IAL L. 5mL 
4 20lAL 2.0mL 
5 25IAL 2.5mL 
6 30lAL 3.0mL 
7 35IAL 3.5mL 
8 40lAL 4.0mL 
9 45IAL 4.5mL 
10 50!!L 5.0mL 
11 55IAL 5.5mL 
12 6Of-lL 6.0mL 
Plasma samples were vortexed to ensure the even distribution of IFN-y in each 
sample. A multichannel pipette was used to transfer 50 !!L of Working Strength conjugate 
to the ELISA microplate wells, and then 50 !!L of the plasma samples was added to the 
appropriate wells of the plate. Lastly, 50 !!L of each of the standards was added to the 
appropriate wells. The plate was thoroughly mixed on a microplate shaker for one minute, 
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and then covered with a lid and incubated at room temperature (22°C ± 5"C) for 120 ± 5 
minutes (out of direct sunlight). 
Working Strength was buffer was prepared by diluting one part Wash Buffer 20X 
Concentrate with 19 parts distilled water, and thoroughly mixed. 
Following incubation, the wells were washed with 400 ilL of Working Strength 
wash buffer for at least six cycles in an automated ELISA plate washer. Once the 
automated washer had finished, the plates were taken out and excess wash buffer was 
tapped upside down on Kimwipes. 100 ilL of Enzyme Substrate Solution was added to 
each well and thoroughly mixed with the microplate shaker. The plate was covered with a 
lid, and incubated at room temperature (22°C ± 5°C) for 30 minutes (out of direct 
sunlight). 
Following incubation, 50 ilL of Enzyme Stopping Solution was added to each well 
and mixed. The Enzyme Stopping Solution was added to the microplate wells following 
the same order and speed as the substrate. 
Within 5 minutes of adding the Enzyme Stopping Solution, the microplate was 
placed in a reader (with 450 nm and 620-650 nm reference filters) and the optical density 
was measured. QuantiFERON-TB Gold IT Analysis Software was used to analyze raw 
data and calculate the results, producing a standard curve. 
